





Aus der Medizinischen Klinik und Poliklinik III Großhadern 
der Ludwig-Maximilians-Universität zu München 
Direktor: Prof. Dr. Dr. Michael von Bergwelt 
 
  
Role of Interferon (IFN)α in ‚Cocktails‘ for the generation of 
(leukemia-derived) dendritic cells (DCleu) from blasts in blood from 
patients (pts) with acute myeloid leukemia (AML) and the induction 




Zum Erwerb des Doktorgrades der Zahnmedizin 
an der Medizinischen Fakultät der 
Ludwig-Maximilians-Universität zu München 
 
vorgelegt von 
Annika Hirn Lopez 






Mit Genehmigung der Medizinischen Fakultät 









Berichterstatter:    Prof. Dr. rer. nat. Helga Schmetzer 
 
 
Mitberichterstatter:    Prof. Dr. M. Albert 
       PD Dr. H.M. Baldauf 
       Prof. Dr. C. Salat 
 
 










Diese Dissertation wurde auf der Basis meiner Publikation im Journal of Immunotherapy verfasst. 
Annika Hirn Lopez, Diana Deen, Zuzanna Fischer, Alexander Rabe, Christian Ansprenger, Kathy 
Stein, Valentin Vogt, Julia Schick, Tanja Kroell, Doris Kraemer, Hans-Jochem Kolb, Johanna Tischer, 
Christoph Schmid and Helga Schmetzer. Role of Interferon (IFN)α in “Cocktails” for the Generation 
of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute 



























1. Zusammenfassung ..................................................................................................................... 5 
2. Abstract ....................................................................................................................................... 7 
3. Introduction ................................................................................................................................. 9 
3.1. Leukemia ............................................................................................................................... 9 
3.1.1. Acute myeloid leukemia (AML)......................................................................................... 9 
3.2. Immune system .................................................................................................................. 10 
3.2.1. Dendritic cells ................................................................................................................ 11 
3.3. DC-generation strategies ................................................................................................... 12 
3.4. Survey of interferon ........................................................................................................... 13 
3.5. Aims of this study .............................................................................................................. 14 
4. Material and Methods ............................................................................................................... 15 
4.1. Sample Collection .............................................................................................................. 15 
4.2. Patients’ characteristics .................................................................................................... 15 
4.3. MNC-DC and WB-DC generation Strategy ........................................................................ 18 
4.3.1. Standard – “MCM-Mimic” (“MCM”) ................................................................................. 19 
4.3.2. Standard - “Picibanil” (“Pici”) .......................................................................................... 19 
4.3.3. Standard - “Calciumionophore” (“Ca”) ............................................................................ 19 
4.3.4. Standard - Interferon-α (“IFN-GIT”) - IFNα, GM-CSF and TNF-α .................................... 20 
4.3.5. “IFN-GI” - IFNα and GM-CSF ......................................................................................... 20 
4.3.6. “IFN” - only IFNα ............................................................................................................ 20 
4.4. Cell characterization by Flow cytometry........................................................................... 21 
4.5. Mixed lymphocyte cultures (MLC) from MNC and WB ..................................................... 23 
4.6. Cytotoxicity fluorolysis assay ........................................................................................... 24 
4.7. Cytometric bead array – CBA ............................................................................................ 24 
4.8. Statistical methods ............................................................................................................. 24 
5. Results ....................................................................................................................................... 25 
5.1. DC-generation from leukemic AML- and healthy-samples .............................................. 25 
2 
 
5.1.1. DC-generation from AML-MNC and healthy-MNC was less effective with “IFN-GIT” 
compared to standard DC-generating methods, however with comparable DC-subtype 
compositions found in “successful cases”’ ............................................................................... 25 
5.2. DC-generation from CML-MNC .......................................................................................... 27 
5.2.1. DC-generation from CML-MNC with “IFN-GIT” compared to “MCM” was similar and DC-
subtype composition comparable ............................................................................................. 27 
5.2.2. Comparable DC-subtype composition with “IFN-GIT” from AML-MNC and CML-MNC... 27 
5.3. DC-generation from leukemic WB-samples ...................................................................... 27 
5.3.1. DC-generation from AML-WB-samples was less effective with “IFN-GIT” compared to 
standard methods, however with comparable DC-subtype compositions found in “successful 
cases” ...................................................................................................................................... 27 
5.3.2. “IFN-GIT” was the most successful IFNα-containing DC-method ................................... 28 
5.4. Quality of DC-generation - ”Ranking” ............................................................................... 28 
5.4.1. Quality of DC-generation with different methods from AML-MNC ................................... 30 
5.4.1.1. “MCM” and “Pici” were the “best” or “second” best DC-generating methods compared 
to at least two other standard methods .................................................................................... 30 
5.4.1.2.“MCM” was ranked as the DC-generating method yielding highest (“excellent”) DC-
subtype values ......................................................................................................................... 30 
5.4.2. Quality of DC-generation with different methods from AML-WB ..................................... 30 
5.4.2.1.“MCM” was ranked as the “best” and “second best” DC-generating methods compared 
to at least two other standard methods .................................................................................... 30 
5.4.2.2. “MCM” was ranked as the DC-generating method yielding highest (“excellent”) DC-
subtype values ......................................................................................................................... 31 
5.4.2.3. Compared to other IFNα-containing methods “IFN-GIT” was ranked as “the best” DC-
generating method ................................................................................................................... 31 
5.4.2.4. None of the IFNα-containing DC-generating methods was ranked as DC-generating 
method yielding highest DC-subtype values ............................................................................ 31 
5.5.  Analysis of blast-proliferation in AML-WB-samples ....................................................... 33 
5.5.1. Addition of “IFN-GI” to AML-WB did not induce blast-proliferation .................................. 33 
5.6. T-cells’ antileukemic functionality after stimulation with “MNC”, “DC” or without 
stimulation in AML-MNC- and AML-WB-samples .................................................................... 33 
5.6.1. In most cases antileukemic activity of “DC”-stimulation T-cells was improved compared to 
“MNC”- stimulated.................................................................................................................... 34 
3 
 
5.6.2. Antileukemic activity of “WB-DC-IFN-GI”-stimulated T-cells was effective ...................... 36 
5.6.3. Proportions of leukemia-derived DC correlated (“highly significantly”) with T-cells’ 
antileukemic activity after DC-stimulation ................................................................................. 36 
5.7. Clinical response to immunotherapy ................................................................................ 38 
5.7.1 Proportions of leukemia-derived DCs correlate with a higher response rate of patients to 
immunotherapy ........................................................................................................................ 38 
5.8. Cytokine levels of DC-culture supernatants tested with CBA ......................................... 38 
5.8.1. Higher release of anti-inflammatory cytokine IL-10, antitumor-response-related cytokines 
IL-2, IL-12p70, TNF-α, IFN-γ and inflammatory cytokines IL-6, IL-8, MCP-1 was found in 
healthy-MNC-DC-compared to AML-MNC-DC-cultures ........................................................... 40 
5.8.2. Release of antitumor response, anti-inflammatory and inflammatory cytokines were lower 
in “IFN-GIT” DC-culture supernatants compared to “pooled” AML-DC-culture supernatants 
(“MCM”, “Pici”, “Ca”) ................................................................................................................ 40 
5.8.3. Higher release of antitumor response, inflammatory and anti-inflammatory cytokines 
found in AML-WB-DC- vs. AML-MNC-DC-pooled-culture supernatants ................................... 41 
5.8.4. Higher release of inflammatory and anti-inflammatory cytokines was found in 
supernatants from AML-WB-DC-cultures (pooled data; “MCM”, “Pici”, “Ca”, “IFN-GIT”) 
compared to AML ”WB-control”................................................................................................ 41 
5.8.5. Higher release of antitumor response, inflammatory and anti-inflammatory cytokines was 
found in supernatants from AML-WB-DC “IFN-GIT” cultures compared to AML”WB-control” ... 42 
5.8.6. Addition of ”IFN-GIT” to WB  increased the release of inflammatory cytokines IL-8 and 
MCP-1 compared to other IFNα-containing Kits ....................................................................... 42 
5.9. Conclusions from results .................................................................................................. 43 
6. Discussion................................................................................................................................. 44 
6.1. AML and treatment strategies ........................................................................................... 44 
6.2. IFNα in different therapies ................................................................................................. 45 
6.3. Dendritic cells – professional antigen presenting cells ................................................... 46 
6.4. DCleu-generation from blast-containing MNC and WB with IFNα-containing media ...... 47 
6.5. Improvement of T-cells’ antileukemic reactivity after stimulation with “IFN-GIT”, 
“MCM” or “Pici” pre-treated (DCleu/DC-containing) blood ...................................................... 48 
6.6. IFNα-based immune modulating therapy of AML patients? ............................................ 49 
7. Conclusion ................................................................................................................................ 51 
8. References ................................................................................................................................ 52 
4 
 
9. List of tables.............................................................................................................................. 62 
10. List of figures .......................................................................................................................... 63 
11. Abbreviations .......................................................................................................................... 64 
12. List of publications ................................................................................................................. 68 
12.1. Original studies ................................................................................................................ 68 
12.2. Congress contributions ................................................................................................... 69 
13. Danksagung ............................................................................................................................ 72 










(Immuntherapeutische) Strategien zur Stabilisierung von Remissionen durch gezielte Eliminierung 
von im Körper verbliebenen AML-Blasten sind erforderlich. Dendritische Zellen (leukämischer 
Abstammung, DCleu/DC), die aus myeloischen Blasten generiert werden können, verbessern die 
antileukämische T-Zell-Reaktivität und können zur “Installation“ eines immunologischen 
Gedächtnisses führen. Es ist bekannt, dass mit IFNα DC-Methoden DCleu/DC aus Blut von Patienten 
mit chronisch myeloischer Leukämie (CML) generiert werden können. 
In dieser Studie wurde die Fähigkeit verschiedener Interferon Alpha (INFα) DC-Methoden im 
Vergleich zu anderen Standard DC-Methoden untersucht, DCleu /DC aus Blasten in mononukleären 
(MNC) oder Vollblut (WB) - Fraktionen von AML Patienten (pts) herzustellen und diese 
durchflusszytometrisch zu quantifizieren. Nach DCleu/DC-Stimulation in gemischten 
Lymphozytenkulturen (MLC) wurde das Potenzial von T-Zellen untersucht antileukämische 
Zytotoxizität hervorzubringen, die mit verschiedenen DC-Methoden erzielten Ergebnisse verglichen 
und mit DCleu/DC-Anteilen korreliert.  
1. Generierung von DCleu/DC: a) “IFN-GIT“ (enthält GM-CSF+IFNα+TNFα) produzierte DC 
erfolgreich (≥ 10% DC, ≥ 5% DCleu/Zellsuspension) aus AML-MNC [WB] im Durchschnitt (ø) in 54 
[56%], “MCM-Mimic“ in ø76 [75%], “Picibanil“ in ø83 [64%] und “Calcium-Ionophore“ in ø42 [67%] der 
Fälle. Die Anteile der DC-Subtypen in MNC [WB] waren mit allen DC-Methoden vergleichbar. 
b) IFNα-Kombinationen, die nur GM-CSF+IFNα oder nur IFNα enthielten, zeigten im Vergleich zu 
“IFN-GIT“ eine geringe Effizienz DCleu/DC aus MNC [WB] hervorzubringen. 
2. Antileukämische Funktionalität: DCleu/DC-stimulierte T-Zellen zeigten insgesamt eine 
verbesserte Leukämie-Zytotoxizität im Vergleich zu blastenstimulierten - oder unstimulierten T-Zellen. 
Die höchste Blastenvermehrung wurde nach Stimulation von T-Zellen mit “IFN-GIT“ vorbehandelten 
MNC/WB-Zellen beobachtet. Insgesamt korrelierte die Wahrscheinlichkeit von Patienten in vivo auf 
eine Immuntherapie anzusprechen oder von DCleu/DC-stimulierten T-Zellen in vitro eine Blastenlyse 
zu erzielen mit hohen Anteilen von DCleu/DC nach DC-Kultur – unabhängig davon, welche DC-
Generierungsmethode verwendet wurde.  
3. Cytokin-Freisetzungsprofile: IL-6, IFN-γ und IL-2-Konzentrationen waren in DC-Kultur-




Unsere Daten zeigen, dass 1) Kultur von WB die in-vivo-Situation von AML Patienten simuliert, 2) 
DC-Generation aus AML-MNC [WB] mit IFNα-haltigen und anderen DC-Methoden möglich ist, 3) 
erfolgreiche IFNα DC-Generation benötigt jedoch GM-CSF+IFNα+TNFα (“IFN-GIT“); “IFN-GIT“ 
produziert allerdings weniger DCleu/DC im Vergleich zu anderen (nicht IFNα) DC-Methoden, 4) T-
Zellen, die mit “IFN-GIT“- (bzw anderen DC-Methoden) vorbehandelten (DCleu/DC-haltigem) Blut 
stimuliert worden waren, erbrachten eine vergleichbare antileukämische Zytotoxizität, allerdings 
wurde bei Fällen ohne erreichte Blastenlyse nach “IFN-GIT“-Vorbehandlung eine stark erhöhte 
Blasten-Proliferation beobachtet. 
Neue immuntherapeutische Strategien sind nötig um erreichte Remissionen in AML Patienten zu 
erhalten und residuale leukämische Blasten zu eliminieren. DC leu, eventuell im Körper nach Gabe 
immunmodulatorisch wirksamen Substanzen generiert, könnten dazu geeignet sein T-Zellen zu 







(Immunotherapeutic) strategies to stabilize remissions by specific elimination of residual AML-blasts 
are needed. DCleu/DC generated from myeloid blasts improve antileukemic T-cell-reactivity and install 
T-cell memory. IFNα-DC-methods produce DCleu from chronic myeloid leukemia patients’ blood. 
In this study various interferon alfa (INFα) containing DC-methods in comparison to other standard 
DC-methods were studied to produce DCleu (evaluated by flowcytometry) from AML patients’ blast-
containing mononuclear (MNC) or whole blood (WB). After DCleu/DC-stimulation in mixed lymphocyte 
cultures (MLC) T-cells’ potential to gain antileukemic cytotoxicity was studied and correlated with 
different DC-methods and DCleu/DC counts.  
1. Generation of DCleu/DC: a) “IFN-GIT“ (containing GM-CSF+IFNα+TNFα) produced DC 
successfully (≥ 10% DC, ≥ 5% DCleu/cells) from AML-MNC [WB] in ø54 [56%], “MCM-Mimic“ in ø76 
[75%], “Picibanil“ in ø83 [64%] and “Calcium-ionophore“ in ø42 [67%] of cases. Proportions of DC-
subtypes in MNC [WB] were comparable with all DC-methods. 
b) IFNα-combinations containing only GM-CSF+IFNα or only IFNα showed low efficiency to produce 
DCleu/DC from MNC [WB] compared to “IFN-GIT“. 
2. Antileukemic functionality: DCleu/DC-stimulated T-cells showed improved leukemia-cytotoxicity 
compared to blast- or unstimulated T-cells. The highest blast-proliferation (=insufficient T-cells) was 
seen with “IFN-GIT“ DC-stimulated T-cells. Probability to respond to immunotherapy or to obtain blast-
lysis of DC-stimulated T-cells correlated with high proportions of DCleu/DC after DC-culture, 
independent of DC-generating methods.  
3. Cytokine-release-profiles: Levels of IL-6, IFN-γ and IL-2 were lower in DC-culture-supernatants 
(from MNC/WB) with “IFN-GIT” compared to MCM”, “Pici” and “Ca” DC-supernatants. 
Our data shows that 1) WB-culture simulates AML patients’ in-vivo-situation, 2) DC-generation is 
possible from AML-MNC [WB] with IFNα-containing and other DC-methods, 3) successful IFNα-DC-
generation requires GM-CSF+IFNα+TNFα (“IFN-GIT”), however, “IFN-GIT“ produces less DCleu/DC 
compared to other (non IFNα) DC-methods, 4) T-cells stimulated with “IFN-GIT”- produced DCleu/DC 
yielded comparable antileukemic cytotoxicity-however in cases without achieved blast-lysis an 
increased blast-proliferation was observed. 
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New immunotherapy strategies are needed to achieve remissions in AML patients and to eliminate 
residual leukemic blasts. DCleu, possibly generated in the body after administration of 
immunomodulatory substances, may be able to reactivate T-cells, mediate antileukemic activity and 





3.1. Leukemia  
Leukemia diseases are divided into myeloid – and lymphocytic leukemia depending on the affected 
cells and their morphological and immunological properties. Both types of malignant diseases are 
further divided into acute or chronic subtypes.1 Acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) are malignant diseases which appear in all age groups though ALL has 
a higher prevalence among the children. Chronic myeloid leukemia (CML) and chronic lymphocytic 
leukemia (CLL) can be seen as geriatric disorders.1 
Secondary acute myeloid leukemia (sAML) is a term to antecedent hematological disorder (ADH) 
such as aplastic anemia (AA), myelodysplasia (MDS) and myeloproliferative disorder (MPN). It can 
also be therapy related occurrence after chemotherapy treatment on AML patients.2 
The myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic stem-cell 
malignancies. MDS-patients have a high tendency to develop AML. Even in 70% of high-risk and in 
10% of low-risk MDS-patients AML occurs. In the past MDS was assumed to be a pre-level of AML.3,4 
Furthermore, chronic myelomonocytic leukemia (CMML) has many characteristics of MDS5. 
 
3.1.1. Acute myeloid leukemia (AML) 
AML is a heterogenous neoplastic disorder arising from disturbed function of hematopoietic stem cells 
(HSC) or progenitor cells, which underlay chromosomal or molecular aberrations6. Abnormally 
accumulation of myeloid blast (≥ 20%) within bone marrow or peripheral blood and in other organs 
cause leukocytosis, anemia and thrombocytopenia in patients. Untreated patients die normally within 
a few months because of leading complications associated with bone mark failure.7 AML can be seen 
as a malignant disease of elderly people. The average age of diagnosis is around 67 years. The high 
age of AML patients makes the therapy and prognose more challenging.4,8 The patients can be 
divided into three risk groups (favourable – intermediate – adverse) concerning the analyzed 
cytogenetic profile9. The 5-years overall survival (OS) of patients’ ≤ 60 years is less than 20%8. The 
etiology of AML is still not completely discovered and is still under the focus of leukemia research6. 
It is known that leukemogenesis and tumor progression are supported and mediated by vascular 
endothelial growth factors (VEGF), fibroblast growth factors and proteins of angiogenesis. Intensive 
expression of CXC chemokine ligand 4 (CXCR4) and activation of CXCR4-CXCR14 axis play an 
important role in hematopoiesis and involves development of AML.10 Chromosomal aberrations are 
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found on average in 50-80% of AML patients. They are mostly detected by the elderly - and in 
secondary leukemia (sAML) patients. Chromosomal translocations are common cytogenetic 
aberrations. The deletion or loss of chromosomes mostly affects chromosomes 5, 7, Y and 9. 
Normally fusion of genes t (15;17), t (8; 21) or t (16;16) / inv (16) are involved.6 
 
3.2. Immune system 
The immune system is a complex machinery protecting the host from pathogenic microbes, toxic and 
allergenic substances and pre-cancerous and malignant cells. It is divided into the innate- and 
adaptive immune system.11,12 The innate immune system comprises all the parts of immune reactivity 
encoded in germline genes. It includes complement system (protein molecule cascade), Toll-Like 
Receptors (TLRs) and phagocytic cells (DC, macrophages, natural killer (NK), mast cells, eosinophils, 
basophils and neutrophils). The innate immune system induces the immediate immune response 
against foreign invaders. It is the first line defense mechanism equipped with a short-term memory.13 
The adaptive immune system contains B- and T- lymphocytes which induce immune responses 
mediated by their antigen-specific receptors (TCR; T-cell receptors, Ig; B-lymphocyte immunoglobulin 
receptors) expressed on the surfaces of lymphocytes. B-cells mediate humoral functions of adaptive 
immune system. They produce antigen specific antibodies. Both B- and T-lymphocytes are 
responsible for long-term memory.12,13 
Even though the immune system consists of two separate complexes – still they support each other 
and work together. Dendritic cells (DC) are antigen presenting cells (APC) and part of the innate 
immune system. They can be seen as a bridge in the function of immune system. DCs present 
processed foreign antigens on major histocompatibility complex (MHC I, MHC II) molecules to T-cells. 
Recognition of presented antigen by T-cell receptors (TCR) induce T-cell activation and elimination 
of foreign antigens.12 
Not always the immune defense works properly and tumor cells are able to escape the host immune 
system which leads to relapse or progression of tumor disease. One explanation for escape 
mechanism could be defect in NK-cell cytotoxicity against tumor antigens.14 The other possible 
reasons could be; impaired MHC-mediated antigen presentation or anergy function of T-cells through 
downregulation of stimulatory molecules of B-cell surface antigen (B7)15 or increased secretion of 
immunoreceptor (Tim-3) which reduces T-cells IL-2 secretion. IL-2 is obligatory for further activation 
of NK- and T-cells.16 
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Cytokines play a central role in leukemogenesis, in persistence of AML-blasts and thus they have a 
central role in outcome of AML in patients17. Cytokines - released by blast cells or immunoreactive 




3.2.1. Dendritic cells 
Dendritic cells (DCs) are well known antigen presenting cells (APC) of immune system which have a 
high capacity to activate adaptive immune system - induce T-cell stimulation and antitumor response 
against malignant diseases25,26. They are derived from hematopoietic precursor cell in bone marrow 
(BM) and are divided into tree subsets depending on their origin; plasmacytoid DC (pDC), 
conventional DC (cDC1/DC2) and monocyte derived DC (mDC). Conventional DCs have their origin 
from common myeloid progenitor (CMP) cells and plasmacytoid dendritic (pDC) cells from common 
lymphoid progenitors (CLP). For DC-differentiation and maturation DCs need growth  
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Table 1. Cytokines and their functions 
1. Cytokines related to inflammations
2. Cytokines related to antitumor response
3. Cytokines related to antiinflammatory reaction
DC dendritic cells; TH1 T-helper cells 1; TH2 T-helper cells 2; BCDF B-cell differentation factor; NAP-1 neutrophil-activating protein-1; G-




factors such as Fms-related tyrosine kinase-3 (Flt-3) and granulocyte macrophage colony stimulating 
factors (GM-CSF).27 DC subsets have their own phenotype typical surface markers. Plasmacytoid 
DCs express markers such as; CD123, CD303, CD304 and NRP1/BDCA-1, conventional DC1 CD141 
and BDCA-1, and conventional DC2 CD1c, CD11c and CD11b. After migration the periphery DCs 
have a lifespan of days to few months. DC subsets are specialized to respond to different pathogens 
and danger signals. Plasmacytoid DCs sense with their surface and endosomal tool-like-receptors 
7/9 (TLR7/TLR9) and conventional DC1/DC2 with their tool-like-receptors 3/9 (TLR3/TLR9) antigen 
single-stand RNA and double-strand DNA and thus they response inducing release of interferon and 
other cytokines to activate immune system. DCs can be seen as a bridge between innate and adaptive 
immune system. After detection and procession of antigen DCs migrate to secondary lymphoid organs 
as mature-DC to present processed antigen to T-cells.28 
 
3.3. DC-generation strategies 
There are different ways to induce DC-generation. Firstly, DCs can be generated from monocytes 
(CD14+) and progenitor cells (CD34+). Those generated DCs need to be in lymphoid tissue while 
stimulation to gain strong capacity to activate T-cells. For generation and differentiation different 
settings of cytokines such as IL-3, GM-CSF, TNFα, and interferons are used. Secondly, DC-
generation is possible by pulsing DCs with tumor specific antigens and tumor lysate. Thirdly, to use 
DCs antigen-processing and presenting strategies to process proteins with TAA (tumor associated 
antigen).29,30 Advantage of this strategy is to induce antileukemic immune reactions against different 
antigens30,31.  
Fourthly, AML-blasts can be converted to leukemia-derived DC (DCleu) via DC-generation process. In 
vitro based studies show that DC-generating methods based on selected combination of 
immunomodulatory substances can be used to generate functional leukemia-derived DCs (mature 
professional antigen presenting cells) from AML-blasts in mononuclear cell-fractions (MNC).29,32-37 It 
is also approved that in vitro generation of leukemia-derived DC in whole blood (WB) medium is 
possible38,39. Whole blood as a DC-generation medium presents the whole cellular and soluble 
environment (Table 2) and thus it simulates the in vivo situation of body38,39. By using this DC-
generation strategy all antigenic surface-markers of the myeloid blasts together with typical DC-





3.4. Survey of interferon 
Interferons are proteins belonging to group of cytokines which are further divided into three categories; 
interferon alfa (IFNα), interferon beta (IFNβ) and interferon gamma (IFNγ). They are separated into 
two types; interferon-type I (IFNα, IFNβ) and type II (IFNγ).42-44 Several immune cells (NKs, fibroblasts, 
B- and T-cells) produce interferon-type I. Cytokines such as IL-1, IL-2, IL-3, TNFα and GM-CSF 
regulates production of interferons and they are tightly involved in immune reactions of immune 
system. Interferons are known to induce innate immune response against invaded virus or other 
foreign antigens. They can be seen as key players in regulation of major histocompatibility complexes 
(MHC-I/II). Upregulation of MHC-I induces T-cell cytotoxicity activity against viral antigens. Via MHC-
II T-cell helper release higher levels of cytokines which attract other immune cells. Interferon release 
is triggered via antigen binding to membrane Toll-like receptors (TORs) or cytoplasmic receptors.42  
By using the cloning technology production of high amounts of interferon-α has been made possible. 
For the clinical use interferon-α is produced using recombinant (r) DNA technology43. In this study for 
DC-generation interferon-α, IFN-α2b (Intron-A) was used. 
  
Capability to quantify and qualitatively characterize cells involved 
in responses:
1. proportions of AML-blasts
2. proportions of T-cell subtypes
3. proportions of DCleu, DC-subtypes
Conclusion on biological mechanisms / reaction 
profiles:
1. (potentially) increased blast-proportions can be quantif ied
2. Treg, CD4 / CD8 profiles
3. In vivo, DCs in the blood are diff icult to quantify because of 
their migration into the tissue.
Table 2. Advantages of DC-generation from whole blood and clinical relevance
Function
Comments on the clinical relevance / 
implementation in a clinical application
Simulation of physiological system Transferability to the clinic
Analysis of the microenvironment on immunostimulating
and -inhibiting influences possible
Detection of escape or antileukemic mechanisms and possible 
interactions, development of appropriate therapeutic strategies
Functional tests possible Antileukemic responses quantif iable:
decrease / increase of blasts, effector-cell profiles measurable: 
proliferation, subtypes
DC dendritic cell; DCleu leukemia-derived DC;  Treg regulatory T-cell
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Interferon-α type-I is used as therapeutic agent in many hematological diseases such as hairy cell 
leukemia, B- and T-cell lymphoma, chronic myeloid leukemia, multiple myeloma and in solid tumor 
diseases such as renal cell carcinoma, melanoma and kaposi’s sarcoma. Before Imatinib (STI 571, 
Gleevec), a selective inhibitor of the BCR-ABL Tyrosin Kinase was available CML patients were 
treated with Interferon-α (IFNα).45 Further it plays a central role in therapy of hepatitis-C and -B42,44. 
Therapeutic use of interferon-α is based on its’ wide property to elicit antiviral activity, influence cellular 
metabolism and provoke antitumor activity43. It doesn’t influence directly malignant cells. It influences 
immune reactive cells and thus regulates tumor cell proliferation, autophagy function and apoptosis.44 
 
3.5. Aims of this study 
Main intentions of this study were:  
1) to culture blast-rich MNC-samples from AML patients (compared to some CML cases) with several 
DC-generating media MCM-Mimic (“MCM”), Picibanil (“Pici”), Calciumionophore (“Ca”) and in addition 
with media containing IFNα (“IFN”), in order to study the influence of IFNα-containing methods on the 
generation of DC (-subtypes) compared to other DC-methods, 
 2) to culture blast-rich WB-samples (containing the patients’ soluble microenvironment / cytokines) 
from AML patients with these methods,  
3) to investigate the influence of different DC-methods (with a special focus on IFNα-methods) on DC-
subtype compositions, on cytokine profiles (MNC/WB) and on T-cells’ antileukemic activity after 
stimulation with DC-compared to blast-containing MNC,  
4) to correlate findings before and after stimulation of T-cells with DC (generated from IFNα-methods 
compared to other methods) in different settings in a context of released cytokines with the 




4. Material and Methods 
Some experiments (DC-culture, Cytokine analyses) were performed by cand. Dr. med. Dent. Yvonne 
Vokac and cand. Dr. med. Dent. Diana Deen, both members of our group. 
Clinical data of the patients and diagnostic reports were provided by the leukemia laboratories of the 
Med III, University Hospital Großhadern, Munich, the Department for Hematology and Oncology, 
Municipal Hospital, Oldenburg and Department for Hematopoetic Transplantation, Municipal Hospital, 
Augsburg. 
 
4.1. Sample Collection 
Heparinized WB samples were taken from patients in acute phase of AML and CML. MNC were 
prepared from heparinized WB by density-gradient centrifugation (Ficoll-Hypaque, Biochrom, Berlin, 
Germany), washed and finally suspended in phosphate buffered saline (PBS, Biochrom, Berlin, 
Germany) without Ca2+ and Mg2+. 
 
4.2. Patients’ characteristics  
Samples for DC-generation (from MNC and WB) were collected in active stages of the disease from 
AML (n=56), one MDS-CMML (n=1) and from CML (n=3) patients after obtaining informed consent 
(Table 3). The average age of the patients was 49 years (range 21-85 y). The female to male ratio 
was 1:1.28.  
Diagnosis of AML and CML cases was based on the French-American-British (FAB) classification46. 
AML patients presented with different FAB-subtypes: undifferentiated acute myeloblastic leukemia 
(M0: n=5), acute myeloblastic leukemia with minimal maturation (M1: n=11), immature granulocytic 
leukemia (M2: n=12), acute promyelocytic leukemia (M3: n=1), acute myelomonocytic leukemia (M4: 
n=7), acute monocytic leukemia (M5: n=7) and erythroid leukemia (M6: n=3). Three CML patients in 




“Response” to initiated immunotherapy was defined for pts who received a complete remission (CR) 
in the following 3 months after allogeneic SCT/DLI therapy that persisted for at least 9 months, 
remaining pts were “non responders” (Table 3).  
AML and MDS-CMML patients presented with on average 7% B-cells, 14% T-cells, 8% NK-cells, 16% 
Monocytes, 56% blasts. CML patients in blast-crisis presented with on average 3% B-cells, 8% T-
cells, 4% NK-cells, 21% Monocytes, 33% blasts as evaluated by flow cytometry (see below). In cases 
with aberrant expression of CD19+, CD56+, CD14+ on blasts B-, NK-cells or monocytes could not be 
quantified. 
 


















immunotherapy               
T-cell source and the 
stage of disease at  
T-cell harvest 
763 * 38/f AML M0 rel.a.SCT 51 34,33,117,65 x rel.a.SCT 
1280 * 26/m AML M0 dgn. 88 34,13,117,33 NR dgn.,autologous 
569 M * 49/f AML M0 pers. 11 15,33,13,34,19 R nd. 
853 * 33/m  AML M0 rel.a.SCT 50 34,117,33,56 NR nd. 
1172 * 24/m AML M0 dgn. 92 34,117,13,33 x nd. 
480 M * 39/f AML M1 rel. 80 34,117,13,33,56 x nd. 
761 M * 38/f AML M1 pers. 21 34,117,15,65,2,7 NR nd. 
824 * 70/m AML M1 dgn. 68 7,13,34,117 x nd. 
850 * 58/m AML M1 pers. 80 13,33,34,117 R nd. 
1011 ** 57/f AML M1 rel. 88 117,33,34,13,65 R nd. 
1050 ** 32/f sAML M1 dgn. 90 13,33,117,14 x nd. 
1127 ** 61/f AML M1 rel.a.SCT 46 34,117,33,13 NR nd. 
1138 ** 24/m AML M1 rel.a.SCT 50 33,34,117,4,56,65,14 NR nd. 
1144 ** 32/m AML M1 dgn. 66 34,117,13,56,19 R nd. 
1265 ** 47/f AML M1 rel. 45 33,34,117 x nd. 
1283 * 43/f AML M1 rel.a.SCT 24 117,33,15,64,34,56 x nd. 
1243 * 34/m AML M2 rel. 32 34,33,117,13,2 x rel.,autologous 
243 M * 61/m sAML M2 rel. 84 33, 34, 117 x nd. 
427 M * 32/m AML M2 rel. 43 33,65,64,117 NR nd. 
820 * 45/m AML M2 rel. 50 33,34,13,117 R nd. 
821 * 56/f AML M2  rel. 88 33,13,15,65,117,34 NR nd. 
837 * 69/m AML M2 dgn. 39 13,34,117,33,15 x nd. 
914 * 66/m sAML M2 rel. 43 34,33,15,117,14,64 x nd. 
984 * 61/m sAML M2 rel. 42 13,33,34,117 x nd. 
1024 ** 39/m AML M2 pers.rel. 80 33,34,117 NR nd. 
1080 ** 37/f AML M2 rel.a.SCT 34 4,34,117,33,13 x nd. 
1123 ** 70/m AML M2 rel. 47 34,117,33,13 x nd. 
1203 * 69/m sAML M2 dgn. 90 33,34,117 x nd. 
851 * 56/m AML M3 dgn. 73 34,117,33,64,2 x nd. 
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1251 * 82/m AML M4 dgn. 67 15,13,33,64,7,1 x dgn.,autologous 
1285 * 56/f AML M4 dgn. 50 13,33,34,117 x dgn.,autologous 
1330 ** 73/f sAML M4 rel. 79 33, 34 x rel.,autologous 
458 * 47/f AML M4 rel. 15 13,34,117,33 R nd. 
855 * 68/m sAML M4 dgn. 37 13,33,34,65,117 x nd. 
1017 ** 67/m AML M4 pers.rel. 34 33,34,117 x nd. 
755 * 38/f AML M4 rel. 44 34,117,33,13,15 R nd. 
799 * 49/f AML M4 dgn. 60 13,15,33,56,65 R nd. 
1201 * 60/f AML M5 dgn. 49 33,15,65,13,14,4,56 x CR,autologous 
1245 * 48/f AML M5 dgn. 57 56,15,65,33 x dgn.,autologous 
1263 * 40/m AML M5a rel.a.SCT 18 117,33,19,34 NR rel.a.SCT 
1286 * 21/m AML M5 rel.a.SCT 35 34,117,33 x CR,a.SCT 
453 M * 36/m sAML M5  pers.a.SCT 70 13,33,65,4,14,15 x nd. 
793 * 46/f AML M5  pers. 9 15,33,56,65,117 x nd. 
948 * 42/f AML M5 dgn. 42 13,33,34,65,117 R nd. 
481 M * 39/f AML M6 pers. 50 33,34,13,15,117 x nd. 
748 M * 45/m sAML M6 pers. 50 33,34,65,117 x nd. 
1002 * 38/m AML M6 pers.rel.a.SCT 50 4,117,33,34,13,65 R nd. 
1226 * 69/m sAML nd dgn. 65 117,34,33 x dgn.,autologous 
1277 * 45/f sAML nd rel.a.SCT 46 34,117,65,15,13,56 x rel.a.SCT 
1344 ** 60/m sAML nd dgn. 80 13,117,33,34 x dgn.,autologous 
1345 ** 85/m AML nd dgn. 97 34,33,13,117 x dgn.,autologous 
887 * 59/f 
MDS-
CMML nd pers. 8 33,34,117,14,64 
x 
nd. 
1056 ** 27/m sAML nd dgn. 42 13,33,117,34,15 x nd. 
1143 ** 46/f AML nd rel.a.SCT 75 117,34,33,13,15,56 x nd. 
1171 * 40/m sAML nd pers. 90 34,117,33,13 R nd. 
935 * 45/f sAML nd dgn. 40 34,117,65,13,15,56 NR nd. 
954 * 72/f sAML nd pers. 43 34,33,117,15 NR nd. 
1228 * 67/m CML nd dgn./BC 80 33,34,117,56 x nd. 
1267 * 46/m CML nd dgn./AP 11 15,33,34,117,19,56 x nd. 
1275 * 61/f CML nd dgn./CP 8 34, 117 R nd. 
AML acute myeloid leukemia; sAML secondary AML; CML chronic myeloid leukemia; MDS-CMML myelodysplastic syndrome-chronic 
myelomonocytic leukemia; CR complete remission; DC dendritic cells; dgn diagnosis; rel relapse; pers persisting diease; CP chronic phase 
CML; AP accelerated phase CML; BC blast crisis CML; SCT stem cell transplantation; IC Bla immunocytologically detected blasts; nd not done; 
x pts without immunotherapy or with criteria not fulfilled; R responder; NR non-responder; bold letters indicate blast markers usef for DC leu-





4.3. MNC-DC and WB-DC generation Strategy 
All of the substances used for DC-generation are approved for human treatment. 
DCs were cultured in 12-multiwell tissue culture plates from MNC and WB in X-vivo15 (Lonza, 
Belgum) media supplemented with different immunomodulatory factors (Table 4)29,33-35.47. MNC- and 
heparinized WB-samples were diluted to a total volume of 2ml with X-vivo15 fetal calf serum free 
medium (FCS). The cell counts were adjusted adequately to MNC and WB media and cultured 
accordingly. After culture supernatants were harvested and used for cytokine analyses. Part of the 
cells after culture were used for FACS-analyses to evaluate efficient DC-generation, the remaining 







Mode of Action Culture Time References
"MCM" *
GM-CSF, IL-4, TNFα, IL-1ß, 
IL-6, PGE2, FL




10-14 d Kremser, et al.35 
Dreyßig, et al.29                                                                      
"Pici" *
GM-CSF, IL-4, lysate from 
Streptococcus pyogenes, 
PGE2





"Ca" * IL-4, A23187




















10-12 d Cortes, et al.34
"IFN-GITZ" * GM-CSF, IFNα, TNFα, Zylexis
Cytokine based DC-
differentiation
10-12 d Ansprenger, et al.47
DC-generating 
Method/Medium
Table 4. DC-generating Methods
DC-generating methods; medium, stimulating substances, mode of action and culture times are given
DC dendritic cells; d Days; GM-CSF granulocyte macrophage-colony stimulating factor;  IFNα interferon alfa; TNFα tumor necrosis factor alfa; FL 

































4.3.1. Standard – “MCM-Mimic” (“MCM”)  
The generation of DCs from 2.5 x 106 MNC/mL or 2-5 x 106 WB cells/mL was performed in “MCM” 
medium containing 800 U/mL granulocyte macrophage – colony stimulating factor (GM-CSF, Essex 
Pharma, Munich, Germany), 500 U/mL Interleukin IL-4 (Cell Concepts, Umkirch, Germany), and 40 
ng/mL FLT3-Ligand (FL, PromoCell, Heidelberg, Germany). After 3 - 5 days the same amount of the 
cytokines was added into the culture. Half medium exchange was done on day 5 - 7. Concentrations 
were adjusted to 150 ng/mL IL-6 (Cell Concepts), 5 ng/mL (10 ng/mL WB) IL-1β (Cell Concepts), 
1µg/mL Prostaglandin E2 (PGE2, Pfizer, Vienna, Austria), and 200 U/mL (10 ng/mL WB) Tumor 
necrosis factor (TNF-α, Cell Concepts). Moreover 500 U/mL IL-4, 40 ng/mL FL and 800 U/mL GM-
CSF were added. After 9 - 12 days, cells were harvested and used for subsequent experiments.29,32,35  
 
4.3.2. Standard - “Picibanil” (“Pici”)  
The generation of DCs with “Pici” was performed from 1 - 1.25 x 106 MNC/mL or 2-5 x 106 WB 
cells/mL in the presence of 500 U/mL (400 U/mL WB) GM-CSF and 250 U/mL IL-4. After 3-4 days 
the same amount of same cytokines were added into WB-culture. After 5 - 7 days in culture, 10 
µL/mL OK - 432 a lysis product of Streptococcus pyogenes, which has nonspecific 
immunomodulatory effect (Chugai Pharmaceuticals, Kamakura City, Japan) and 1µg/mL PGE2 were 
added. Cells were harvested after 8 - 10 days in culture and used for subsequent experiments. 
29,32,35  
 
4.3.3. Standard - “Calciumionophore” (“Ca”) 
DCs were generated from 7 x 105 MNC/mL or 2-5 x 106 WB cells/mL in the presence of 375 ng/mL 
“Ca” A23187 Calcimycin, a Calciumionophore and antibiotic (Sigma-Aldrich, Thum, Germany) and 




4.3.4. Standard - Interferon-α (“IFN-GIT”) - IFNα, GM-CSF and TNF-α   
DCs were generated from 2-2.5 x 106 MNC/mL or 2-5 x 106 WB cells/mL in “IFN-GIT” medium in the 
presence of 800 U/mL GM-CSF and 500 U/mL IFNα (Essex Pharma, Munich, Germany). After 2 - 4 
days of culture the same amount of cytokines was added. After 7 - 9 days the same procedure was 
repeated and in addition 10 ng/mL TNF-α added into the culture. Cells were harvested after 8 - 11 
days and used for subsequent experiments.33,47 
With the attempt to improve the T-cell stimulating capacity of DC we cocultured in some parallel 
experiments MNC-DC with inactivated Parapox ovis Virus (Pfizer, AH, Inc. formerly Baypamun from 
Bayer, Inc.) in addition to the “IFN-GIT” method. Lyophilized products were resolved in aqua ad 
injectionem as recommended, resulting in an end-concentration of 1.25 mg/ml (2.3 IFN-units) in 
culture.47 
 
4.3.5. “IFN-GI” - IFNα and GM-CSF  
DCs were generated from 2-2.5 x 106 MNC/mL or 2-5 x 106 WB cells/mL in “IFN-GI” medium in the 
presence of 800 U/mL (5µL/mL WB) GM-CSF and 500 U/mL (5µL/mL WB) IFNα. After 2 - 4 and 7 - 
8 days of culture the same amount of cytokines was added. Cells were harvested after 8 - 11 days 
and used for subsequent experiments.33,34  
 
4.3.6. “IFN” - only IFNα 
DCs were generated from 2-2.5 x 106 MNC/mL or 2-5 x 106 WB cells/mL in “IFN-I” medium in the 
presence of 500 U/mL (5µL/mL WB) IFNα. After 2 - 4 and 7 - 8 days of culture the same amount of 





4.4. Cell characterization by Flow cytometry  
With a panel of mouse monoclonal antibodies (moAbs) directly conjucated with fluorescein 
isothiocyanate (FITCa), phycoerythrin (PEb), tandem Cy7-PE conjugation (PC7c) or allophycocyanin 
(APCd) flow cytometric analyses were carried out to evaluate and quantify amounts and phenotypes 
of leukemic cells, B-, T- and natural killer (NK) cells and DC in the MNC- and WB-samples. Labeled 
antibodies were provided by Becton Dickinson (Heidelberg, Germany [CD1ab, CD1ba, CD14c, CD15d, 
CD71c, CD206d, 7AADc and CCR7c]), Immunotec/Beckmann Coulter (Krefeld, Germany [CD1ab, 
CD3a, CD19c, CD33d, CD56b, CD80b, CD117b,d, CD206b, CD34a,c,CD65a and CD83a]) and Caltag 
(Hamburg, Germany [CD1ab,CD13c,CD34dand CD86a]).  
MNC, WB or cultured cells were suspended in phosphate buffered saline (PBS) with 20% fetal calf 
serum (Biochrome) and incubated with specific moAbs. Isotype controls according to manufacturers’ 
instructions as described earlier using a Calibur Flow Cytometer (Becton Dickinson, BD) and Cell 
Quest data software (BD) were performed.29,32,35,47 For analysis and quantification of lymphocytes, 
monocytes and leukemic cells before culture, the total MNC - and WB - fractions were gated. 
Composition of cells before or after conversion to DC was analyzed using patient-specific “blast”-
staining antibodies in combination with ”DC”-staining antibodies. After culture several DC-subtypes 
(Table 5) were quantified and calculated as described32,36,48,49: “migratory mature DC” (DC 
coexpressing the migration marker CCR7), viable DC (DC negative for 7AAD), leukemia-derived DC 
(DC coexpressing both blast and DC markers, DCleu). DCleu were quantified in the DC-fraction 
(DCleu/DC), the blast-fraction (blasts converted to DC) as well as in the total MNC- or WB-fraction 
(DCleu/cells [MNC or WB]). After culture only samples with ≥10% blasts in MNC or WB qualified for 
DC-subtype analysis. We defined DC- generation as successful if at least ≥10% DC and ≥5% 
DCleu/cells (MNC or WB) suspension could be evaluated after culture29,35. For quantification of 
migratory mature CCR7+ DC in the DC-fraction of at least 10% DC were postulated. We also studied 
induced blast-proliferation (CD71+ blasts) in the blast population before and after culture in some 
(n=8) “IFN-I” WB-cultures and in “WB-controls” without any immunomodulatory substances. Only WB-





Further we developed a ranking - strategy to subdivide and analyze the whole data obtained 
according to DC-subtype qualities. Two different approaches were applied: ranking 1) according to 
the best achieved DC-subtype values compared to at least two other parallelly tested standard DC-
methods (“MCM”, ”Pici”, ”Ca”, ”IFN-GIT”), 2) applying an independent criteria-catalogue subdividing 
results in five different DC-generating categories (excellent, excellent-high, high, sufficient and not 
sufficient [Table 6]). In both ranking categories presuppositions as given above were applied.  
 




Blasts in MNC or WB
 Blasts Bla  / cells Bla+(e.g. CD15, 33, 34, 65, 117) ≥ 10 % Bla / cells Schmetzer, et al.36
DCs in MNC or WB
 DC DC / cells DC+(e.g. CD1b, 80, 86, 206 ) *  ≥ 10 % DC / cells
leukemia-derived DC DCleu / cells DC
+ Bla+ ≥ 5% DCleu / cells, ≥10 % DC, ≥ 10 % Bla
blasts converted to DC in 
Blast-fraction 
DCleu / bla DC
+ Bla+ ≥ 5% DCleu / cells, ≥ 10 % DC, ≥ 10 % Bla
DCleu in DC-fraction DCleu / DC DC
+ Bla+ ≥ 5% DCleu / cells, ≥ 10 % DC, ≥ 10 % Bla
migratory mature 
DC in DC-fraction 
DCmigr / DC CCR7
+,DC +  ≥ 10 % DC / cells
Grabrucker, et al.32
Sanchez-Sanchez, et al.48
viable DC in DC-fraction DCviable / DC 7AAD
- , DC+ ≥ 10 % DC / cells
Grabrucker, et al.32
Philpott, et al.49
T-cells in MNC or WB
CD3+ T-cells CD3+ T-cells CD3+ total T-cell population
Vogt, et al.37
Sallusto, et al.51
* DC marker, w hich w asn´t expressed on naive blasts but w hich achieved the highest expression rate in the suspension after culture; DCleu leukemia-derived 
DC in different cell-fractions (in blasts-, in DCs-, in MNC- or in WB-fractions) after culture.
Table 5. Cellular subtypes as evaluated by flow cytometry
Name of cellular subtypes, abbreviations, surface-marker-profiles, presuppositions and criteria for analysis are given.
Schmetzer, et al.36 
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Moreover three tested IFNα-containing WB-DC-Methods (“IFN-GIT”, ”IFN-GI”, ”IFN-I”) were 
compared and ranked as described above in order to evaluate categories and the best DC-subtype 
values gained.  
 
4.5. Mixed lymphocyte cultures (MLC) from MNC and WB 
CD3+ T-cells (“effector” T-cells) were positively selected (Milteney Biotech, Bergisch-Gladbach, 
Germany) as described earlier37,50,51 from AML-MNC from patients at first diagnosis (n=7), in remission 
(n=1), at relapse (n=2) or after allogenic SCT (n=4, Table 3). ”Èffector” T-cells (1x106 T-cells/mL) were 
cocultured with “stimulator cells”: irradiated (20 Gy) AML blast-containing MNC (25x103 “MNC”/mL) 
and in parallel with irradiated DCleu-containing MNC-DC (25x103 “MNC-DC”/mL) as described 
earlier29,32,35,40. In analogy “effector“ T-cells were cocultured with AML-blast-containing WB (25x103 
“WB” cells/mL) and DCleu-containing WB-DC (25x103 “WB-DC”/mL). WB-samples were not irradiated. 
Stimulation conditions and culture times were comparable with AML-MNC-MLC. After MLC fluorolysis 
assays were carried out as described below.29,32,35,40 
  
not sufficient
sufficient  13 - 10  7 - 5  10 - 5  14 - 10
high 19 - 14  11 - 8  15 - 11  20 - 15
Table 6. Criteria-catalogue to rank quantity and quality of DC-subtypes after DC-generation in AML-MNC or in AML-WB-samples 
according to different DC-generating categories (ranking2)
%DC/cells %DCleu/cells %DCleu/DC %DCmigr/DC *
Presuppositions of cell-subtype-proportions for ranking (MNC or WB)
Ranking category
> 25 > 15
< 10 < 5
Ranking of DC-subtype-qualities and -quantities as performed by defining "the best" and "second best" DC-generating method compared to at least tw o 
other parallelly tested DC-methods. Moreover a ranking-strategy w as defined applying an independent criteria-catalogue based on proportions of DC-
subtypes (DC/cells: DC generated, DCleu/cells: leukemia-derived DC generated in cellsuspension, DCleu/DC: DCleu in DC-fraction, DCmigr:migratory mature DC 
in DC-fraction) found after culture.
excellent-high 25 - 20  15 - 12  25 - 16  30 - 21
excellent
< 5 < 10
> 25 > 30
* migratory mature DCs were not available in all cell samples
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4.6. Cytotoxicity fluorolysis assay  
Using a Fluorolysis Assay the antileukemic activity of “effector” T-cells was measured by counting 
viable (blast) target-cells labeled with specific fluorochrome conjugated antibodies before and after 
“effector” T-cell (E) contact. “MNC-DC” [”WB-DC”] or “MNC” [”WB”] stimulated T-cells from AML 
patients (=autologous) or from patients after SCT and unprimed T-cells as a control were cocultured 
in 1.5mL Eppendorf tubes with thawn target blasts (T) as described.29,32,35,40  
 
4.7. Cytometric bead array – CBA 
For evaluation of cytokines (IL-2, IL-6, IL-10, IL-12p70, TNF-α, IFN-γ)18,21-24 and chemokines (CXCL8 
(=IL-8), CCL2 (=MCP-1))19,20 serum samples or supernatants collected from DC-cultures (“WB-DC”, 
“MNC-DC”) the BD TH1/TH2-CBA-kit II (Becton Dickson, BD, Biosciences) were used (Table 1). 
Detection limits were given by the company (BD) as follows: IL-2 5.49 pg/ml, IL-6 8.98 pg/ml, IL-8 
9.03 pg/ml, IL-10 8.63 pg/ml, IL12p70 8.93 pg/ml, MCP-1 9.37 pg/ml, TNF-α 7.22 pg/ml and IFN-γ 
8.47 pg/ml. Each 500 µl of serum and supernatants, were stored at -80°C until the day of analysis. 
Positive and negative controls of the standard serial dilutions of the respective cytokines and 
chemokines were used. 
20 µl mixed human TH1/TH2 Cytokine capture beads, 20 µl PE Detection Reagent and 20 µl of each 
cytokine samples were incubated for three hours at room temperature in 96-well assay plates (BD 
Falcon). The samples were washed after incubation with 220 µl Wash Buffer, thereafter 96-well plates 
were centrifuged at 200g for five minutes. Before sample analysis with a LSRII Flow cytometer (BD 
Biosciences, Germany) the bead pellets were resuspended with Wash Buffer. 
 
4.8. Statistical methods 
Data was presented as mean, median, range and standard deviations. Two-tailed t-, Anova- or Chi-
Quadrat-tests were conducted with a personal computer using Excel 2010/16 (Microsoft). For CBA 
data evaluation a special software (cytokine ArrayTM FCAP 3.0, BD) was used. Differences were 
considered as “highly significant” (***) in cases with p-values < 0.005, as “significant” (**) with p-values 





The focus of our work was to study the DCleu-generation capability of various IFNα-containing - 
compared to other DC-generating media (“MCM”, “Pici” or “Ca”) from blast-rich MNC- (n=54) and WB-
samples (n=15) from AML patients. We applied a ranking strategy to evaluate the quality and quantity 
of the generated DCs. We also studied DC-generation from blast-rich CML-MNC-samples (n=3). The 
WB-culture strategy was developed by us – thereby simulating the most physiological situation. 
Moreover, we investigated the influence of these DCleu on T-cells’ antileukemic activity and the soluble 
microenvironment after stimulation of T-cells in MLC and correlated findings with the antileukemic 
activity of T-cells.  
Our first approach was to study DC-generation data from mononuclear cell samples and later WB 
from AML patients and healthy probands. We evaluated the whole DC-generation data by using 
crated DC-subtype proportions for successful DC-generation. After culture only samples with ≥10% 
blasts in MNC or WB qualified for DC-subtype analysis. We defined DC- generation as successful if 
at least ≥10% DC and ≥5% DCleu/cells (MNC or WB) suspension could be evaluated after culture. In 
this part we used only data of successful DC-generation for further analysis (Figure 1). 
 
5.1. DC-generation from leukemic AML- and healthy-samples 
5.1.1. DC-generation from AML-MNC and healthy-MNC was less effective with “IFN-GIT” 
compared to standard DC-generating methods, however with comparable DC-subtype 
compositions found in “successful cases”’ 
We compared proportions of AML-MNC-DC-subtypes generated with “IFN-GIT” compared to three 
other standard DC-methods. “MCM” was successful in 41 of 54 (76%) cases, “Pici” in 43 of 52 (83%), 
“Ca” in 21 of 50 (42%) and “IFN-GIT” in 28 of 52 (54%) cases. A successful generation of DCleu/DC 
was however possible in every given case with at least one of the DC-methods. In cases with 
successful DC-generation proportions of DC-subtypes obtained with “IFN-GIT” were comparable to 
the other three standard methods: proportion of DC/cells obtained with “IFN-GIT” was Ø 27% (range 
10-69%) vs. “MCM” Ø 26% (range10-61%), vs. “Pici” Ø 24% (range 10-64%) and vs. “Ca” Ø 30% 
(range 10-74%). Moreover, no significant differences were found between the four methods with 






The generation of DC from healthy-MNC with “MCM” was successful in 9 of 9 (100%) cases, “Pici” in 
7 of 9 (78%), “Ca” in 7 of 9 (78%) and “IFN-GIT” in 6 of 8 (75%) cases. The total amount of DC/cells 
in healthy-MNC-samples after generation with “IFN-GIT” was Ø 25% (range 14-40%) vs. “MCM” Ø 
28% (range10-52%), vs. “Pici” Ø 25% (range 10-41%) and vs. “Ca” Ø 22% (range 13-70%). No 
significant differences were found either between the four standard methods with respect to DC-
subtypes (e.g. DCviable/DC, DCmigr/DC, monocytes converted to DC, data not shown). 
A parallel comparison of various IFNα-containing methods (“IFN-GIT”, “IFN-GI”, ”IFN-I”) with AML-
MNC-samples (n=3) showed, that DC-generation was successful only in 1 of 3 (33%) cases with “IFN-
GI” or “IFN-I” cultures. “IFN-GIT” was successful in 2 of 3 (67%) cases. “MCM” in all three cases (data 
not shown).  
A parallel comparison of “IFN-GIT” and “IFN-GITZ” with “MCM” of AML-MNC (n=3) showed that “IFN-
GIT” and “IFN-GITZ” were successful in 1 of 3 (33%) cases, “MCM” in 3 of 3 (100%) cases (data not 
shown).  
Figure 1. DC-subtypes generated from AML-MNC. Average proportions of DC-subtypes and standard-
deviations are presented. Only cases with successful DC-generation (≥ 10% DC and ≥ 5% DC leu in cell-
suspensions) are given.













In summary, we show that “IFN-GIT” was a successful DC-generating method (≥10% DC/cells, ≥5% 
DCleu/cells [MNC]) in ø 54% of AML cases, whereas “MCM” was successful in ø 76% and “Pici” in ø 
83% of cases. ø amounts of DC-subtypes generated, however were comparable in cases of 
successful DC-generation with all methods. Other IFNα-containing DC-methods (“IFN-GI”, “IFN-I”, 
“IFN-GITZ”) decreased efficiency of DC-generation. 
 
5.2. DC-generation from CML-MNC  
5.2.1. DC-generation from CML-MNC with “IFN-GIT” compared to “MCM” was similar and 
DC-subtype composition comparable  
We could show comparable (non significantly different) proportions of DC-subtypes (DCleu/bla: Ø 48% 
vs. 45%, DCleu/cells: Ø 15% vs.18%, DC/cells: Ø 22% vs. 31%, DCleu/DC: Ø 56% vs. 54%, DCmigr/DC: 
Ø 45% vs. 26%, DCviable/DC: Ø 16% vs.19%) after culture of CML-MNC with “IFN-GIT” vs. “MCM” 
(data not shown). 
 
5.2.2. Comparable DC-subtype composition with “IFN-GIT” from AML-MNC and CML-MNC 
DC-subtypes after DC-generation from AML- (n=28) and CML- (n=2) samples were similar (DCleu/bla: 
Ø 34% vs. 48%, DCleu/cells: Ø 17% vs.15%, DC/cells: Ø 27% vs. 22%, DCleu/DC: Ø 63% vs. 56%, 
DCmigr/DC: Ø 31% vs. 45%, DCviable/DC: Ø 38% vs. 16%), data not shown. 
In summary, we showed a comparable efficiency of “IFN-GIT” vs. “MCM” to generate DC from CML-
MNC and comparable DC-subtype compositions in AML vs. CML cases. 
 
5.3. DC-generation from leukemic WB-samples 
5.3.1. DC-generation from AML-WB-samples was less effective with “IFN-GIT” compared to 
standard methods, however with comparable DC-subtype compositions found in “successful 
cases” 
“MCM” was successful to generate DC in 9 of 12 (75%), “Pici” in 7 of 11 (64%), “Ca” in 8 of 12 (67%) 
and “IFN-GIT” in 5 of 9 (56%) cases from AML-WB. No significant differences in DC-subtype 




5.3.2. “IFN-GIT” was the most successful IFNα-containing DC-method 
”IFN-GIT” was successful in 5 of 9 (56%), “IFN-GI” in 5 of 15 (33%), “IFN-I” in 1 of 10 (10%), “MCM” 
in 75%, “Pici” in 64% and “Ca” in 67% of cases. No significant differences were seen in DC-subtypes 
obtained with all methods (data not shown).  
In summary, the success of “IFN-GIT” or other IFNα-containing methods to generate DCleu from AML-
WB was lower compared to all other cytokine-based DC-generating methods. However, proportions 
of DC-subtypes were comparable with all successful methods. Moreover “IFN-GIT” was the most 
effective IFNα-containing method to generate DCs. 
 
5.4. Quality of DC-generation - ”Ranking” 
We quantified DC-subtypes after culture of AML-MNC [WB] with four standard-media and different 
IFNα-combinations (WB) and applied two ranking-categorizations to evaluate the quality of DC-
generation (Figure 2). The applied ranking approaches were:  
1) according to the best achieved DC-subtype values compared to at least two other parallelly tested 
standard DC-methods (“MCM”, ”Pici”, ”Ca”, ”IFN-GIT”),  
2) applying an independent criteria-catalogue subdividing results in five different DC-generating 



























1st, the best 37 33 23 15 1st, the best 40 20 30 11
2nd best 24 43 18 17 2nd best 40 30 20 11
3rd best 35 16 16 39 3rd best 20 30 10 44
4th best 4 8 43 29 4th best 0 20 40 33
Ʃ (n) 46 49 44 46 Ʃ (n) 10 10 10 9





















excellent 17 10 11 9 excellent 20 10 10 0
excellent-high 13 14 9 7 excellent-high 0 0 0 11
high 17 10 14 11 high 20 30 20 11
sufficient 33 47 9 28 sufficient 60 30 30 22
not sufficient 20 19 57 45 not sufficient 0 30 40 56
Σ (n) 46 49 44 46 Ʃ (n) 10 10 10 9
Figure 2. Quality of DC-generation from AML-MNC and AML-WB according to ranking-criteria. 
Ranking 1 (a): the best DC-values compared to at least two other parallelly tested standard DC-methods, Ranking 
2 (b): based on DC-subtype quality categories as given in Table 6. AML-MNC-DC ranking (left side), AML-WB-DC 
ranking (right side). The bold letters represent results obtained with the majority of cases with DC-method. The 
arrows point the results of IFNα-containing DC-method "IFN-GIT" .
DC-cultures from MNC

























































































5.4.1. Quality of DC-generation with different methods from AML-MNC 
5.4.1.1. “MCM” and “Pici” were the “best” or “second” best DC-generating methods compared 
to at least two other standard methods 
“MCM” was ranked as the “best method” in 17 of 46 (37%), “Pici” in 16 of 48 (33%), “Ca” in 10 of 43 
(23%) cases, whereas “IFN-GIT” was ranked as the “best method” in 7 of 46 (15%) cases. However, 
compared to other standard methods “IFN-GIT” was ranked in 18 of 46 (39%) cases on the “third” 
and in 13 of 46 (29%) on the “fourth” position with respect to DC-generation criteria (Fig. 2a, left side).   
 
5.4.1.2.“MCM” was ranked as the DC-generating method yielding highest (“excellent”) DC-
subtype values 
As shown in Figure 2b on the left side “MCM” was ranked as “excellent” DC-generating method in 8 
of 46 (17%), “Pici” in 5 of 49 (10%), “Ca” in 5 of 44 (11%) cases, whereas “IFN-GIT” was ranked as 
“excellent” DC-method in 4 of 46 (9%) cases (Table 6). “IFN-GIT” was ranked as “excellent-high” in 3 
of 46 (7%), “MCM” in 6 of 46 (13%), “Pici” in 7 of 49 (14%) and “Ca” in 4 of 44 (9%) cases. 
Furthermore, compared to other standard methods “IFN-GIT” was ranked in 21 of 46 (45%) cases as 
“not sufficient” (Fig. 2b, left side).  
In summary, “IFN-GIT” did not qualify as method to generate regularly sufficient as well as high 
amounts of DC-subtypes from AML-MNC. 
 
5.4.2. Quality of DC-generation with different methods from AML-WB 
5.4.2.1.“MCM” was ranked as the “best” and “second best” DC-generating methods 
compared to at least two other standard methods 
“MCM” was ranked as the “best method” in 4 of 10 (40%), “Pici” in 2 of 10 (20%), “Ca” in 3 of 10 (30%) 
cases, whereas “IFN-GIT” was ranked as the “best method” in 1 of 9 (11%) cases. Results up to the 




5.4.2.2. “MCM” was ranked as the DC-generating method yielding highest (“excellent”) DC-
subtype values 
“MCM” was ranked as “excellent” in 2 of 10 (20%), “Ca” in 1 of 10 (10%), “Pici” in 1 of 10 (10%) cases, 
whereas “IFN-GIT” could not be ranked as “excellent” DC-method. “IFN-GIT” was ranked as 
“excellent-high” in 1 of 9 (11%). However, compared to other standard methods “IFN-GIT” was ranked 
in 5 of 9 (56%) cases as “not sufficient”. “MCM” was not ranked as not sufficient DC-method (Figure 
2b, left side).  
 
5.4.2.3. Compared to other IFNα-containing methods “IFN-GIT” was ranked as “the best” DC-
generating method  
“IFN-GIT” was ”the best” IFNα-containing DC-method in 3 of 5 (60%) cases, followed by “IFN-GI” in 
2 of 5 (40%) cases (Figure 3a).  
 
5.4.2.4. None of the IFNα-containing DC-generating methods was ranked as DC-generating 
method yielding highest DC-subtype values 
None of the three IFNα-containing DC-methods qualified as “excellent” or “excellent-high”. “IFN-GIT” 
was “sufficient” in 2 of 5 (40%) cases, followed by “IFN-GI” in 1 of 5 (20%) cases. “IFN-I” was ranked 
as “not sufficient” in all cases (Figure 3b).  
In summary, “IFN-GIT” is no preferential method to generate regularly sufficient and high amounts of 























1st, the best 60 40 0  excellent 0 0 0
2nd best 40 40 20 excellent-high 0 0 0
3th best 0 20 80  high 0 0 0
Ʃ (n) 5 5 5  sufficient 40 20 0
 not sufficient 60 80 100
Ʃ (n) 5 5 5
b) Ranking 2
DC-cultures from WB
Figure 3. Quality of DC-generation from AML-WB-samples with IFNα-containing methods 
according to ranking criteria.
Ranking 1 (a): the best DC-values compared to at least two other parallelly tested IFNα-containing 
DC-methods, Ranking 2 (b): the best DC-value based on DC-subtype-quantity-categories as given 










































5.5. Analysis of blast-proliferation in AML-WB-samples 
Only WB-samples with >10% CD71+ proliferating blasts before culture were included in proliferation 
analysis. 
 
5.5.1. Addition of “IFN-GI” to AML-WB did not induce blast-proliferation 
Proliferation (CD71+ blasts) before and after DC-culture (n=8) from WB-samples in “IFN-GI” and “WB” 
(WB without any responsemodifiers as control) mediums were quantified and did not show induced 
blast-proliferation in “IFN-GI” compared to WB-control (data not shown). 
 
In summary, addition of “IFN-GI” to WB DC-cultures did not induce blast-proliferation.  
 
5.6. T-cells’ antileukemic functionality after stimulation with “MNC”, “DC” or without 
stimulation in AML-MNC- and AML-WB-samples 
DC-stimulation in general improves the antileukemic (lytic) function of T-cells after MLC. “Effector” T-
cells used were autologous patients’ T-cells (n= 7) or T-cells from patients after allogenic SCT (n=4). 
Cases were subdivided in those with achieved blast-lytic activity (Lysis) or non-achieved blast-lysis 
(No-lysis) after 3h and/or 24h incubation of effector-cells with target-cells. For the following analyses 







5.6.1. In most cases antileukemic activity of “DC”-stimulation T-cells was improved compared 
to “MNC”- stimulated  
The blast-lytic activity of “DC”- vs. “MNC”-stimulation was regularly improved (pooling all results 
obtained after “DC”-stimulation, Figure 4a, left side): 36% (13 of 36) vs. 22% (2 of 9) of cases 
"DC" "MNC" "us" 











n/n 4/11  7/11 4/7 3/7
Figure 4. Potential of antileukemic activity of "IFN-GIT"-stimulated T-cells vs. other 
"DC"- ("MCM", "Pici"), "MNC"-stimulated or unstimulated T-cells. Antileukemic activity 
of effector T-cells was quantified after 3h or/and 24h incubation with "blast-target" cells. 
Arrows point to high proportions of blast in cases without achieved blast-lysis after "IFN-
GIT" DC-stimulation.
a) Pooled results of T-cells' antileukemic activity after "DC"-stimulation ("MCM","Pici","IFN-GIT") compared 
to "MNC" and unstimulated T-cells ("us", left side), ø % of blasts lysed/ blast-proliferation (right side)
b) T-cells' antileukemic activity after "DC"-stimulation w ith "MCM" vs. "Pici" vs. "IFN-GIT" (all cases 
included, left side), ø % of blasts lysed/blast-proliferation (rights side)
c) T-cells' best antileukemic activity (comparison betw een tw o parallel DC-methods) after "DC"-



























































































































































































































achieved antileukemic activity (p=0.05, t-test). Activity of unstimulated T-cells was comparable to 
“DC”-stimulated T-cells’ activity 31% (4 of 13 cases). 
Average proportions of lysed blasts were 21% vs. 39% vs. 41% after “DC”- vs. “MNC”- vs. 
unstimulated T-cells. Proportions of blasts were increased (in cases without lysis) ø by 119% vs. 85% 
vs. 82% (Figure 4a, right side). 
Studying individual DC-methods’ capacity to initiate T-cells’ antileukemic activity showed, that “Pici” 
was with 43% (3 of 7 cases) the most effective method, followed by “MCM” with 36% (4 of 11) cases 
and “IFN-GIT” with 33% (6 of 18) cases (Figure 4b, left side). Average proportions of lysed blasts 
were 20% vs. 18% vs. 22% of blasts after “Pici”- vs. “MCM”- vs. “IFN-GIT” DC-stimulation. On average 
blast-proportions (in cases without lysis) increased by 118% vs. 84% vs. 141% (Fig. 4b, right side) 
after “Pici” vs. “MCM” vs. “IFN-GIT” DC-stimulation.  
Parallel comparison of DC-methods’ (Figure 4c, left side) capacity to initiate T-cells’ antileukemic 
activity (comparison of “MCM” vs. “IFN-GIT” and “Pici” vs. “IFN-GIT”) revealed that “IFN-GIT” was 
superior to “MCM” in 7 of 11 cases (64%), however compared to “Pici” only in 3 of 7 cases (43%, 
Figure 4c, left side). Average proportions of lysed blasts were 14% vs. 23% after “MCM”- vs. “IFN-
GIT” DC-stimulation and 16% vs. 32% after “Pici”- vs. “IFN-GIT” DC-stimulation. Average increased 
blast-proportions (in cases without lysis) were 98% vs.153% of blasts after “MCM”- vs. ”IFN-GIT” DC-
stimulation and 118% vs. 124% after “Pici”- vs. “IFN-GIT” DC-stimulation (Figure 4c, right side). 
The average DC-subtype proportions of DCleu/blasts, DC/cells and DCleu/DC in pooled “IFN-GIT”, 
“MCM” and “Pici” DC-samples were comparable in cases without lysis/with lysis. Differences of 
DCleu/cells between the cases without lysis and with lysis 19% vs. 31% were tendentially significant 
(p=0.05, data not shown). For DC-subtype analysis we used only cases with successful DC-
generation. 
In summary, we demonstrated a higher antileukemic lytic activity of “DC”-stimulated compared to 
“MNC”-stimulated or “us” T-cells. “IFN-GIT” DC-stimulated T-cells achieved in minority of cases 
antileukemic activity compared to “MCM” and “Pici”. “IFN-GIT” DC-stimulated T-cells improved blast-




5.6.2. Antileukemic activity of “WB-DC-IFN-GI”-stimulated T-cells was effective  
After 3 and 24 hours of coculture of “WB-DC” (“IFN-GI”) -stimulated T-cells with naïve AML-blasts 
showed in 3 of 6 cases (50%) blast-lysis with Ø18% (range 1-34%) of lysed blasts. In cases with no-
lysis Ø190% (range 9-280%) increased blast-proportions were found. T-cells stimulated with “WB-
control” resulted in 4 of 6 (67%) cases with blast-lysis with Ø44% (range 17-84%) of lysed blasts. In 
cases with no-lysis Ø140% (range 0-280%) increased blast-populations were found (data not shown). 
In summary, T-cells’ stimulation with “WB-DC-IFN-GI” showed lower antileukemic activity and higher 
blast-proportions after coculture with AML-blasts compared to “WB-control”-stimulated T-cells 
(Fluorolysis assay). 
 
5.6.3. Proportions of leukemia-derived DC correlated (“highly significantly”) with T-cells’ 
antileukemic activity after DC-stimulation 
Including cases with and without successful DC-generation we evaluated cut-off values for several 
DC-subtypes (generated with “IFN-GIT”, “MCM” or “Pici”), that allowed the most predictive separation 
of cases in those with later on achieved blast-lysis and in those without achieved antileukemic lytic 
activity (Figure 5). In both groups (“IFN-GIT” vs. “MCM”/ “Pici”) we could demonstrate, that high 
proportions of DCleu/bla, DC/cells, DCleu/cells and DCleu/DC generated correlated with a later on 
achieved higher antileukemic lytic activity. Achieved lysis highly significantly correlated with 
proportions of blasts converted to DCleu (p=0.0004 / Figure 5a). Comparable results were seen 





Figure 5. Proportions of DC-subtypes (DCleu/bla: blast converted to DC in blast-fraction, DC/cells: DC total, 
DCleu/DC: DCleu in DC-fraction), which induced T-cell antileukemic activity (blast-lysis) or non-activity (non-
lysis) after DC-stimulation in MLC. DCs were generated with IFNα-containing “IFN-GIT” (left side) and “MCM” 
or “Pici” (right side) media. Cut-off values could be found that predicted antileukemic T-cell activity after 
DCleu/DC-stimulation: antileukemic activity correlated directly and in part significantly with generated DC- and 
DCleu-counts. Cases with or without successful DC-generation were used for cut-off presentation. 
 
In summary, we showed a direct (and in part highly significant) correlation of DC-subtype-proportions 































































































































5.7. Clinical response to immunotherapy 
5.7.1 Proportions of leukemia-derived DCs correlate with a higher response rate of patients 
to immunotherapy 
We correlated proportions of DC-subtypes generated with “IFN-GIT” and “the best DC-method”. 
Evaluating cut-off values for several DC-subtypes, that allowed the most predictive separation of 
cases in “clinical responders” (n=11) and “non-responders” to immunotherapy (n=11) for both groups 
(“IFN-GIT” vs. “the best DC-method”) we could again correlate higher proportions of DCs (DC/cells, 
DCleu/bla, DCleu/cells, DCleu/DC) with a higher rate (although non significant) of patients responding to 
immunotherapy (data not shown). Only cases with successful DC-generation were included (data not 
shown). 
In summary, we demonstrated a direct (non significant) correlation of DC-subtype-proportions 
(generated with “IFN-GIT” and “the best DC-method”) with pts’ response to initiated immunotherapy. 
 
5.8. Cytokine levels of DC-culture supernatants tested with CBA 
We quantified cytokine (IL-2, IL-6, IL-8, IL-10, IL-12p70, TNF-α, IFN-γ, MCP-1) levels in DC-culture 
supernatants of AML-MNC- or WB- and healthy-MNC-samples after DC-generation with “IFN-GIT” or 
other standard DC-generating methods (“MCM”, “Pici”, “Ca”). Furthermore, we compared cytokine 
levels of different IFNα- (“IFN-GI”, “IFN-I”) containing DC-WB-culture supernatants. Only significant 





Figure 6. Cytokine levels obtained with CBA-assay in healthy-MNC-DC- and the p-values of 
pooled DC-supernants x and "MCM,Pici,Ca" vs."IFN-GIT" ° (a), in AML-MNC-DC- and the p-
values of pooled DC-supernants x and "MCM,Pici,Ca" vs. "IFN-GIT" ° (b), and AML-WB-DC-
culture supernants and the p-values of pooled DC-supernants x and "MCM,Pici,Ca,IFN-GIT" 
vs."WB-control" ° (c). DCs were generated from MNC (WB) in “IFN-GIT”, “MCM”, “Pici” and 
“Ca” media (and "WB-control" without added responsemodifiers). ** indicates p-values between 
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5.8.1. Higher release of anti-inflammatory cytokine IL-10, antitumor-response-related 
cytokines IL-2, IL-12p70, TNF-α, IFN-γ and inflammatory cytokines IL-6, IL-8, MCP-1 was 
found in healthy-MNC-DC-compared to AML-MNC-DC-cultures 
Pooling all cytokine values (obtained with “MCM”, “Pici”, “Ca” and “IFN” from AML pts. vs. healthy-
samples) is given in Figure 6: IL-6, IL-8, TNF-α, IFN-γ and MCP-1 release profiles from AML-MNC-
DC-supernatants vs. healthy-MNC-DC were “highly significantly” different or “significantly” different. 
IL-6: ø 1394 pg/ml vs. ø 7639 pg/ml (p=0.00005); IL-8: ø 3194 pg/ml vs. ø 6077 pg/ml (p=0.004); 
TNF-α: ø 4 pg/ml vs. ø 294 pg/ml (p=0.0005); IFN-γ: ø 6 pg/ml vs. ø 858 pg/ml (p=0.0002); MCP-1: 
ø 2542 pg/ml vs. ø 6205 pg/ml (p=0.006). IL-10: ø 4 pg/ml vs. ø 62 pg/ml (p=0.01) and IL-2: ø 11 
pg/ml vs. ø 59 pg/ml (p=0.03) were “significantly” different. IL-12p70 levels were not significantly 
different in AML-MNC-DC-supernatants vs. healthy-MNC-DC ø 11 pg/ml vs. ø 29 pg/ml (p=0.2).  
“MCM”,”Pici” and “Ca” vs. “IFN-GIT” supernatants from healthy-MNC-DC showed “highly significantly” 
different IL-6 (p=0.001) and IL-8 (p=0.001) and “significantly” different MCP-1 (p=0.01) levels. MCP-
1 level of “MCM”,”Pici”, “Ca” and “IFN-GIT” was “highly significantly” (p=0.0001) different. In AML-
MNC-DC-supernatants “MCM”,”Pici” and “Ca” vs. “IFN-GIT” showed “significantly” different IL-6 
(p=0.0003) levels. IL-6 level of “MCM”,”Pici”, “Ca” and “IFN-GIT” was “highly significantly” 
(p=0.000002) different (Figure 6a,b). 
In summary, antitumor-response-related cytokines IFN-γ, TNF-α and MCP-1 were “highly 
significantly” or “significantly” higher and anti-inflammatory cytokine IL-10 “significantly” higher in 
culture supernatants of healthy-MNC-DC- compared to AML-MNC-DC-cultures. 
 
5.8.2. Release of antitumor response, anti-inflammatory and inflammatory cytokines were 
lower in “IFN-GIT” DC-culture supernatants compared to “pooled” AML-DC-culture 
supernatants (“MCM”, “Pici”, “Ca”) 
Higher cytokine levels were found (“MCM”/”Pici”/“Ca”) in AML-MNC-DC-supernatants (n=138, pooled 
data) compared to “IFN-GIT” AML-MNC-DC- (n=22) supernatants. Only levels of inflammatory IL-6 
were “significantly” higher in “pooled” vs. “IFN-GIT” DC-culture supernatants: ø 1669 pg/ml vs. ø 190 
pg/ml, p=0.01. Levels of the remaining cytokines (IFN-γ, IL-2) were not significantly different in “IFN-
GIT” vs. pooled AML-MNC-DC supernatants; IFN-γ: ø 2 pg/ml vs. ø 14 pg/ml; IL-2: ø 7 pg/ml vs. ø 
13 pg/ml (data not shown).  
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In summary, results obtained with ”MCM”, “Pici” and “Ca” supernatants represented more the healthy 
cytokine profile than “IFN-GIT”. 
 
5.8.3. Higher release of antitumor response, inflammatory and anti-inflammatory cytokines 
found in AML-WB-DC- vs. AML-MNC-DC-pooled-culture supernatants 
Comparison of WB-DC- and MNC-DC-supernatants showed “highly significantly” higher cytokine 
levels of IL-6, IL-8, IL-10, TNF-α and MCP-1 in WB-DC- vs. MNC-DC-supernatants (Figure 6); IL-6: 
ø 10447 pg/ml vs. ø 1414 pg/ml (p=0.0001); IL-8: ø 9311 pg/ml vs. ø 3193 pg/ml (p=0.002); IL-10: ø 
11 pg/ml vs.4 pg/ml (p=0.001); TNF-α: ø 9 pg/ml vs. ø 4 pg/ml (p=0.002); MCP-1: ø 21990 pg/ml vs. 
ø 2541 pg/ml (p=0.003). Levels of the remaining cytokines (IFN-γ, IL-2) were (non significantly) higher 
in AML-WB-DC- vs. AML-MNC-DC-supernatants. IFN-γ: ø 20 pg/ml vs. ø 6 pg/ml (p=0.3); IL-2: ø 25 
pg/ml vs. ø 11 pg/ml (p=0.2).  
In summary, “(highly) significantly” higher release of inflammatory cytokines IL-6, IL-8 as well as IL-
10, TNF-α and MCP-1 was found in AML-WB-DC- compared to AML-MNC-DC-culture supernatants.  
 
5.8.4. Higher release of inflammatory and anti-inflammatory cytokines was found in 
supernatants from AML-WB-DC-cultures (pooled data; “MCM”, “Pici”, “Ca”, “IFN-GIT”) 
compared to AML ”WB-control”  
Addition of DC-culture media to cultures significantly increased IL-6, IL-8 and IL-10 release levels 
compared to “WB-control” (Figure 6). IL-6: ø10447 pg/ml vs. ø 28 pg/ml (p=0.01); IL-8: ø 9311 pg/ml 
vs. ø 2385 pg/ml (p=0.03); IL-10: ø 11 pg/ml vs. ø 4 pg/ml (p=0.04). Levels of IFN-γ and IL-12 were 
not significantly different in pooled AML-WB-DC- vs. “WB-control”-cultures. Cytokine release levels of 
the IFN-γ: ø 19 pg/ml vs. ø 5 pg/ml; IL-12: ø 9 pg/ml vs. ø 8 pg/ml. Cytokine profiles of IL-6 
(p=0.000000004) and IL-8 (p=0.000001) in “MCM”, “Pici”, “Ca”, “IFN-GIT” and “WB-control” 
supernatants showed “highly significantly” different levels (Figure 6c). 
In summary, addition of DC-culture media to cells (results of all DC-methods pooled) significantly 
increased the release of inflammatory and anti-inflammatory cytokines compared with “WB-control”. 
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5.8.5. Higher release of antitumor response, inflammatory and anti-inflammatory cytokines 
was found in supernatants from AML-WB-DC “IFN-GIT” cultures compared to AML”WB-
control” 
“(Tendentially) significantly” higher release level of IL-10, TNF-α and MCP-1 was measured in WB-
DC “IFN-GIT” supernatants compared to “WB-control”; IL-10: ø 12 pg/ml vs. ø 4 pg/ml (p=0.07); TNF-
α: ø 14 pg/ml vs. ø 8 pg/ml (p=0.07); MCP-1: ø 15019 pg/ml vs. ø 1883 pg/ml (p=0.02 [Figure 6]). 
Levels of the remaining cytokines (IFN-γ, IL-12) were not significantly different in “IFN-GIT” vs. “WB-
control” cultures. IFN-γ: ø 9 pg/ml vs. ø 5 pg/ml; IL-12: ø 12 pg/ml vs. ø 8 pg/ml. 
In summary, addition of “IFN-GIT” to WB increased (significantly) the release IL-10, TNF-α and MCP-
1 compared to “WB-control”. 
 
5.8.6. Addition of ”IFN-GIT” to WB increased the release of inflammatory cytokines IL-8 and 
MCP-1 compared to other IFNα-containing Kits 
Release of IL-8, MCP-1 and IFN-γ was “tendentially significantly” higher in DC-culture supernatants 
of “IFN-GIT” vs. “IFN-GI” vs. “IFN-I”; IL8: ø 4305 pg/ml vs. ø 2736 pg/ml vs. ø 216 pg/ml (p=0.1); 
MCP-1: ø 15019 pg/ml vs. ø 6151 pg/ml vs. ø 1166 pg/ml (p=0.1); IFN-γ: ø 9 pg/ml vs. ø 7 pg/ml vs. 
ø 15 pg/ml (p=0.1). Levels of IL-12 were not significantly different in “IFN-GIT” vs. IFNα-containing 
Kits (“IFN-GI”, “IFN-I”). IL-12: ø 12 pg/ml vs. ø 11 pg/ml vs. ø 14 pg/ml (data not shown). 
In summary, “IFN-GIT” increased the release of inflammatory cytokines IL-8 and MCP-1 in DC-




5.9. Conclusions from results 
Our Data shows 1) that WB is a good tool to simulate AML patients’ in vivo situation, 2) DC-generation 
is possible from AML-MNC (WB) with IFNα-containing methods and with other DC-methods without 
induction of blasts’ proliferation, 3) successful DC-generation with IFNα needs the addition of GM-
CSF and TNFα (“IFN-GIT”). However, “IFN-GIT” is inferior to produce quantitatively and qualitatively 
DCleu/DC compared to “MCM” and “Pici”, 4) “IFN-GIT” DC-stimulated T-cells yield comparable 
antileukemic cytotoxicity - however, in cases without achieved blast-lysis a very high increase of blasts 
was observed, 5) antileukemic activity goes along with high DCleu/DC-counts in “IFN-GIT”, “MCM”, 
“Pici” and “Ca” cultures, 6) high DCleu/DC-counts correlated with patients’ achieved response to 
immunotherapy, 7) addition of any DC-media to WB produces more favorable cytokine release profile 
compared to “WB-control” and 8) addition of “IFN-GIT” produces a more favorable cytokine release 





6.1. AML and treatment strategies  
Only 20-30% of treated AML patients reach long term leukemia-free-survival52. SCT is the only 
curative treatment option with strong antileukemic-effect though it is associated with high risk of 
treatment related mortality52-55. 
With immunotherapeutic strategies such as DLI after SCT in combination with post remission 
chemotherapy remissions can be retained, restored and survival can be prolonged54,56-58, although 
those patients also have a risk to relapse59. Recently promising (less aggressive) immunotherapeutic 
strategies have been developed increasing immunological effects or mechanisms or targeting directly 
tumor-cells e.g.: adoptive transfer of immune reactive T-, NK-cells or antibodies (targeting tumor cells 
or immunosuppressive cells), vaccinations with DCs pulsed with leukemic antigens, manipulated 
AML-blasts or tumor lysates60.61. Immunomodulatory strategies include e.g. the application of 
immune-attractants such as chemokines to attract T- and NK-cells, anti-immunosuppressants such 
as TGFβ-blockers and cyclooxygenase inhibitors, immune responsemodifiers (cytokines) and blast-
modulatory substances60.62. These immunotherapeutic and immunomodulatory strategies are efficient 
tools to support and activate the patients’ immune system. All of these strategies could result in 
enriched or specifically (re)activated immune effector-cells, a modified microenvironment, deactivated 
immune escape mechanisms in combination with established immunological memory63,64. Many of 
these strategies are mild therapies with low toxicity, and a potential of high efficiency, although often 
without creation of an immunological memory. Moreover, many immunotherapies need Gmp-facilities 
and infectiological testing which are technically demanding, expensive and lead to limited cellular 
products (e.g.: designed antibodies or T-cells). 
A conversion of leukemic-blasts to leukemia-derived DCs by DCleu/DC generating methods mildly 
modulate blasts to antigen presenting cells – presenting the whole leukemic antigen-repertoire of 
individual patients, leading to a (re)activation of the immune system and the installation of an 
immunological memory. Those DCleu could either be generated from blast-containing MNC, prepared 
and adoptively transferred to patients. Alternatively, the generation of DCleu could be induced after 
patients’ treatment with approved drugs inducing DCleu-production in vivo. Here we wanted to evaluate 
the role of IFNα-containing drug-combinations (for ex vivo and in vivo use) to generate DCleu as 




The use of combined selected (approved) immunomodulatory substances in vivo to AML patients 
offers many advantages: the clinical use is easy, circumvention of technically demanding procedures 
and high costs, it can be repeated as required converting (residual) blasts to DCleu with a potential to 
migrate to tissues and to induce a humoral and cellular immunological memory.     
6.2. IFNα in different therapies  
Recombinant human IFNα with/without pegylation increasing IFNα’s half-life time42-44 is already used 
in the therapy of hairy cell leukemia, CML, B- and T-cell lymphomas, melanoma, hepatitis-B (HBV) 
and -C (HCV), renal carcinoma and Karposi’s sarcoma and has shown immunological effect65,66. In 
both acute HCV and HBV infections early IFNα treatment alone or (in case of HCV) combined with 
Ribavirin can eliminate the virus, induce remissions of the disease and reduce the risk of 
hepatocellular carcinoma67,68. In high-risk melanoma stage II and III a high-dose IFNα therapy has 
shown significant improvements of overall survival (OS) and RFS rates69,70. 
Before development of the tyrosinkinase-inhibitor Imatinib was discovered IFNα was used as a 
monotherapy or in combination with cytarabine in CML patients before or after SCT45. Therapy of 
early chronic CML with IFNα has been shown to induce hematological remissions in 60-80% of CML 
patients. Although with single IFNα-therapy major cytogenetic remissions could be achieved in 35-
55% of CML patients34 in an international randomized Phase III Study of 1106 CML patients a major 
cytogenetic response could be induced in 85% of the patients (n=553) with Imatinib but only in 22% 
of patients (n=553) using IFNα-Cytarabine71. In another Imatinib-IFNα combination trial of CML 
patients’ molecular remissions could be achieved in some pts after withdrawal of Imatinib, but 
continuation of IFNα therapy. Interestingly higher levels of Proteinase-3 and PR-1-specific cytotoxic 
T-cells (PR1-CTL) were detected during the IFNα-therapy in those patients (pointing to a specific 
installation of immunological antileukemic response), but not during Imatinib therapy-although 





6.3. Dendritic cells – professional antigen presenting cells  
DCs are well known APC with a high capacity to initiate T-cell immune responses against tumor 
cells25,26. DCs can be generated from monocytes (CD14+) and loaded with tumor-specific leukemia 
associated antigens (LAA)29,31. DC-vaccinations of patients with (ex vivo generated, modified) 
monocyte derived DC have been approved to patients with melanoma, B-cell lymphoma and prostate 
cancer. They have been shown to be save, giving rise to antitumor immune responses and tumor 
regression.73-76 Disadvantages of these DC-generation strategies are, limitations to particular 
antigens. Furthermore, it is an expensive and time-consuming methodological strategy. The 
advantage of a monocyte-derived process for a clinical use is its potential to be standardized and to 
install an immunological memory77,78.  
DCleu are known to be generated efficiently in vitro by conversion of AML-blasts in MNC-fractions to 
mature APCs by using DC-generating methods, combinations of DC-inducing and maturating 
substances such as “MCM-mimic”, “Picibanil” or “Ca”29,32,35,40 and cytokines like TNFα, GM-CSF or 
PGE2 inducing hematopoetic myeloid cell differentiation, in combination with a danger signaling and 
DCleu/DC maturation79-84. Here we can confirm, that in vitro a DC-generation from AML-MNC is 
possible (using “MCM”, “Pici” or “Ca”) in every given patient, thereby overcoming blasts’ resistance to 
be converted to DCleu29,30,32,35.We show in addition, that in vitro DCleu/DC-generation using these 
methods is possible from WB, containing whole cellular and soluble environment of these blasts 
thereby simulating the situation in the body85,86. That means, that both AML-MNC- and WB-blasts are 
converted to DCleu using these DC-methods and present the whole antigenic surface-markers of the 
individual patients’ myeloid blasts together with typical DC-antigen-markers. Without need of 
knowledge of distinct leukemic antigens29,32,35,36,41. In general DC obtained with both DC-generating 
strategies (using monocyte-derived LAA-loaded or leukemia-derived DC) are applicable for an 
adoptive transfer in patients to induce antileukemic DC-triggering effects against AML-blasts32,37,87,88. 
In addition in vitro DC stimulated T-cells could also be applied to AML patients. However, these 
strategies need Gmp-facilities, infectiological testings, yield limited cellular products and are 
expensive. Thus, an elegant and intelligent strategy could be an in vivo application of (preclinically 
tested) immunomodulatory substance combinations (Kits) to generate DCleu from AML-blasts in vivo-




6.4. DCleu-generation from blast-containing MNC and WB with IFNα-containing media 
We wanted to find out, whether DCleu/DC can be generated from blast-containing AML- (and from 
some CML-samples) MNC as well as from WB using IFNα-containing methods compared to other 
DC-methods. IFNα-containing DC-generating methods: “IFN-GIT” and “IFN-GI” contained GM-CSF, 
with /without TNFα.  
GM-CSF is a glycoprotein stimulating proliferation and differentiation of myeloid stem cells to mature 
granulocytes as well as recruitment of dendritic competent cells79. Clinically GM-CSF is therefore 
applicated after chemotherapy (prophylactically or therapeutically) or after SCT to improve 
regeneration of hematopoetic cells in patients with leukemia or solid tumors, to shorten times of 
neutropenia (thereby reducing neutropenia-associated mortality, incidence of infections, 
administration rate of antibiotics and hospitalization times) and to activate monocytes and DC in vivo 
without inducing proliferation of myeloid blasts in patients with AML79-83. As an acute phase protein 
TNFα is involved in inflammatory processes, as a “regulatory cytokine” for cellular processes (e.g. 
cellular survival/apoptosis), as activator of the immune system and “inductor of DC-maturation”84,89,90. 
Clinically TNFα has been used for the treatment of soft tissue tumors (in high local concentrations) 
and systemically (in low concentrations) for the treatment of advanced neoplasia, e.g. metastatic 
melanoma91.92. Since IFNα has been used clinically in the treatment of melanoma, CML, hepatitis-B 
and -C67-71, it could qualify as immunomodulatory substance to be applicated directly (together with 
GM-CSF +/- TNFα) to patients - resulting in an in vivo production of DCleu. 
We could show that a DC-generation with IFNα-containing method (especially “IFN-GIT”) in general 
is possible from MNC- as well as WB-samples from healthy- as well as from AML-blood donors (giving 
rise to comparable amounts of DCleu/DC in MNC compared to WB). In cases with successful DC-
generation (as defined by us) proportions of viable, migratory, leukemia-derived DC were comparable 
- thereby confirming, that the generation of “leukemia-derived” DC is possible with IFNα-containing 
combinations of immunomodulators as already described by Chen et al33. However, comparing the 
efficiency of a DC-generation according to ranking criteria we could show, that “IFN-GIT” qualified 
less to produce (sufficient) DCleu/DC from AML-samples compared to other DC-methods (“MCM”, 
“Pici”, “Ca”) whereas DCleu/DC from CML-samples could be produced in comparable amounts with 
“MCM” and “IFN-GIT”. We conclude, that IFNα-containing methods might stimulate CML-blasts more 
efficiently than AML-blasts to produce DCleu. This might explain the clinical observation, that IFNα 




Studying the effect of various IFNα-containing Kits (“IFN-GIT”, “IFN-GI”, “IFN-I”) to generate DCleu/DC 
from AML-WB we could show, that Kits containing only IFNα had a very low efficiency to generate 
DCleu/DC at all, whereas the addition of GM-CSF (and even more together with TNFα) to these 
cocktails increased proportions of DCleu/DC- thereby confirming data already published, that GM-CSF 
plays a central role in the ex vivo generation of DCleu/DC33,79. 
We could already show, that the addition of Zylexis increased proportions of mature DC47. Therefore, 
we studied the role of Zylexis (a pox virus – product, known in veterinarian medicine to improve 
immunological reactions, especially of the innate immune system93-95 in case of DC-generation with 
“IFN-GIT” and additionally added Zylexis “IFN-GITZ”. We found, that IFNα-containing “IFN-GIT” and 
“IFN-GITZ” DC-generating methods induced comparable amounts of DC-subtypes. However, “MCM” 
was superior to those IFNα-containing DC-methods. 
An important finding was, that neither the addition of any DC-method “Pici”, “Ca” nor “IFN-GIT”, “IFN-
GI” or “IFN-GITZ” to leukemic WB-samples did induce a blast-proliferation as already shown by us38. 
That means, in general an application of “IFN-GI”, -“GIT” or -“GITZ” to patients could be safe (with 
respect to the risk to induce a blast-proliferation in vivo) and since substances are approved for human 
treatment79-84,89-92. 
 
6.5. Improvement of T-cells’ antileukemic reactivity after stimulation with “IFN-GIT”, 
“MCM” or “Pici” pre-treated (DCleu/DC-containing) blood 
Our intention was to evaluate the potential of the IFNα-containing DC-generating method “IFN-GIT” 
compared to other DC-methods to give rise to antileukemic activity of T-cells after MLC. In the past 
we could already show, that a conversion of AML-blasts to DCleu followed by MLC with T-cells 
improved T-cells’ antileukemic reactivity in the majority of cases. Here we show, that in general (in 
most of the cases) “DC”-stimulated (either “IFN-GIT”, “MCM”, “Pici” pre-treated in MNC) T-cells’ 
induced antileukemic activity compared to “MNC”-stimulated (control without added DC-media) and 
also to unstimulated T-cells’. Interestingly “IFN-GIT” DC-containing cultures improved T-cells’ 
antileukemic activity and showed comparable antileukemic activity to “MCM” and “Pici” pre-treated T-
cells. An important finding was, that cases without achieved blast-lysis by T-cells after stimulation with 
“IFN-GIT” pre-treated blasts (as demonstrated by cytotoxicity assays) were characterized by highest 
increase of blasts-proportions. This could be explained by (possible) IFNα-mediated influences on T-
cells inhibiting their blast-attack (e.g. by inducing escape-mechanisms)96. Another important 
observation was, the finding of a direct correlation of DCleu/DC-counts obtained by any DC-method 
with the achieved antileukemic function of T-cells after MLC with DC-method pre-treated blasts in 
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MLC. Average DCleu/DC-counts obtained with “IFN-GIT”-, “MCM”- and “Pici”-samples after DC-culture 
were comparable pointing to the role of DCleu (- counts) in the mediation of antileukemic reactions. 
This could mean, that 1) an adoptive DCleu/DC-based immunotherapy of AML patients in general 
could contribute to improve antileukemic T-cells’ reactivity, that 2) ”MCM” and “Pici” are superior to 
“IFN-GIT” to generate DCleu/DC-resulting in improved blast-lysis and 3) that “IFN-GIT” pre-treated 
blasts in MNC could only be used for adoptive transfer after preliminary confirmation of ex vivo 
induced T-cells’ blast-lysis after MLC.  
We found reduced cytokine levels in AML-MNC-DC-supernatants of all DC-methods compared to 
supernatants of healthy DC-cultures. Compared to MNC/WB “MCM”-, “Pici”- and “Ca”- supernatants 
“IFN-GIT”- DC culture supernatants were characterized by lower release of IL-2, IL-6, IL-10 and also 
IL-12. Compared to “WB-control” the addition of any DC-generating method improved the average 
release of IFN-γ and MCP-1-pointing to an improved cytokine release profile. We assume, that 
patients’ treatment with immunomodulatory substances change and improve the cytokine release 
profile, which could contribute for patients’ improved response to immunotherapy as postulated by 
other authors17,97,98. Multifactorial analyses (including also cytokine - and chemokine - release - 
profiles, composition of cells of the adaptive and innate immune system) have to be performed to 
further illuminate these findings in correlation with antileukemic activity. 
 
6.6. IFNα-based immune modulating therapy of AML patients? 
Using a culture model with blast-containing WB from AML patients, as developed by us, we could 
show, that the value and DCleu/DC-generating efficiency of various immune modulating treatment 
approaches by using combinations of cytokines, danger-factors and/or DC-maturating substances 
can be tested very well. We found, that DC-generating methods (e.g, “MCM”, “Pici”, “Ca”, “IFN-GIT”) 
qualify to generate DCleu/DC from blast-containing MNC- as well as WB-samples from AML patients 
and could therefore be transfused into patients. Moreover WB-cultures are a good tool to demonstrate 
whether Kits (containing only 1-3 approved drugs) qualify to generate (ex vivo) DCleu/DC, that could 
be transferred to AML patients or whether that Kits could be directly used as immune modulatory 
drugs to treat AML patients inducing DCleu/DC in vivo using blast-containing WB. We could show, that 
DCleu/DC are not regularly produced using “IFN-I” or “IFN-GI” and in general in lower amounts using 
“IFN-GIT” compared to other DC-generating methods. 
It was already shown, that after therapy of CML patients with GM-CSF+IFNα clinical and cytogenetic 
responses can be achieved, that might be due to direct antitumor IFNα effects and possibly in addition 
by transformation of myeloid CML-blasts - approach to treat AML patients with IFNα-containing 
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protocols has already been performed earlier with the aim to produce DC leu in vivo that induce an 
antileukemic response by (specific) T-cell activation. Converted blasts to DCleu – contribute to activate 
leukemia specific immunoreactive cells.34,45 
The clinical use of IFNα for AML patients has been shown to be safe and well tolerated 65,66,99. 
Moreover in 1979 Hill et al. described a ‘modest antitumor effect’ after (unpegylated) IFNα treatment65. 
These antitumor effects are known to be mediated by T-, NK-cells and DC97.  For maintenance of 
these effects continuously high and stable IFNα-levels are necessary. This has been shown to be 
problematic to be induced in serum in AML patients – especially if unpegylated IFNα was used65. So 
far pegylated IFNα has been used in salvage therapies in several clinical AML-trials treating pts at 
relapse, relapse following SCT and also in CR after chemotherapy or after SCT65. It was also shown 
that remissions in AML patients with myelofibrosis can be achieved using PEG-IFNα65,66. Moreover 
the application of GM-CSF and IFNα was shown to induce remissions in 3 of 4 AML patients and in 
2 of 3 ALL patients treated in a salvage therapy81. Although no detailed information about all pts were 
given there are hints, that some patients profited from this therapy (one of the patients still did not 
show any sign of the disease after 3.5 years, another was in CR with chronic GVHD after one year of 
initial relapse, the third showed persisting disease)81.  
Our data show, that IFNα-containing therapies have a potential to induce antileukemic reactivity of T-
cells ex vivo, however only if GM-CSF and TNFα were combined with IFNα. We recommend a careful 
selection of patients in that antileukemic reactivity could be shown in simulated ex vivo settings to 





In conclusion, we could show that with the IFNα-containing “IFN-GIT” DC-method DC-generation is 
possible both from AML-MNC- and -WB-samples, although other standard DC-methods (“MCM” and 
“Pici”) were (in quantity and quality) superior in the ex vivo production of DCleu/DC. Blast-proliferation 
was not induced by any DC-generating method in WB.  
We could show that successful antileukemic activity (induced after MLC of T-cells with DC-containing 
suspensions) correlated with high proportions of DCleu/DC generated with “MCM”, “Pici” and “IFN-
GIT”- pointing to the central role of DCleu/DC in the mediation of antileukemic reactions. Since “IFN-
GIT” produced lower proportions of DCleu/DC (compared to “MCM”, “Pici” and “Ca”) we conclude, that 
– although “IFN-GIT”– treated (blast-containing) MNC or WB can induce antileukemic activity after 
MLC – other DC-generating methods or Kits that result in higher DCleu/DC counts and in consequence 
in superior antileukemic activity compared to “IFN-GIT”. In cases without successful mediation of 
antileukemic reactivity after “IFN-GIT” pre-treated blast-containing “MNC” or “DC” we could even 
detect an increase of blasts - pointing to a possible severe adverse event (SAE) after “IFN-GIT”- 
treatment in vivo. In general, our data point to an important cytokine release profile of IFN-γ and MCP-
1 under the influence of any DC-generating media compared to “WB-control”. 
There is a need to further develop, study and select combinations of immunomodulatory substances 
to generate leukemia-derived DC without inducing blasts’ proliferation, but with a high potential to 
induce specific antileukemic T-cells, that could be used in AML-therapy e.g. to stabilize remissions by 
specific elimination of (residual) AML-blasts.  
Using patients’ WB to simulate the in vivo situation we could show, that DCleu/DC can be generated 
with IFNα-containing Kits (especially “IFN-GIT”), although not on a regular basis. Probably a treatment 
approach using IFNα, TNFα and GM-CSF could give rise to DCleu/DC without induction of blasts’ 
proliferation in vivo followed by generation of antileukemic T-cells - in cases with proven DCleu/DC-
generation in WB. Our ongoing research focuses on the development of Kits, consisting of 2-3 blast 
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